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Abstract 
 
A central event in Alzheimer’s disease is the accumulation of amyloid β (Aβ) 
peptides generated by the proteolytic cleavage of the amyloid precursor protein (APP). 
APP overexpression leads to increased Aβ generation and Alzheimer’s disease in humans 
and altered neuronal migration and increased long term depression in mice.  Conversely, 
reduction of APP expression results in a decreased Aβ levels in mice as well as impaired 
learning and memory and decreased numbers of dendritic spines.  Together these findings 
indicate that therapeutic interventions that aim to restore APP and Aβ levels must do so 
within an ideal range.  To better understand the effects of modulating APP levels, we 
explored the mechanisms regulating APP expression focusing on post-transcriptional 
regulation.  Such regulation can be mediated by RNA regulatory elements such as 
guanine quadruplexes (G-quadruplexes), non-canonical structured RNA motifs that affect 
RNA stability and translation. Presented in this thesis, we identified the G-quadruplex as 
a novel endogenous regulator of APP expression within the APP mRNA in its 
3’untranslated region at residues 3008-3027 (NM_201414.2).  This sequence exhibited 
characteristics of a parallel G-quadruplex structure as revealed by circular dichroism 
spectrophotometry.  Further, as with other G-quadruplexes, the formation of this structure 
was dependent on the presence of potassium concentration. Moreover, we present 
preliminary data demonstrating that FMRP and FXR2P bind to the APP G-quadruplex 
sequence and regulates it expression. 
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Chapter 1: Introduction 
 
BACKGROUND AND SIGNIFICANCE 
 
The first case of Alzheimer’s disease was identified more than 100 years ago and it would 
takes decades more for it to be recognized as the leading cause of the dementia [1]. 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is the most 
common form of dementia [2]. Dementia is a decline in memory, language, and cognitive 
functions that affects an individual’s capacity to perform daily activities or routines [3]. 
People living with AD may begin to have difficulty remembering names or new 
information and may experience depression. As the disease progresses, individuals 
experience impaired judgment, disorientation, changes in behavior or mood, as well as 
difficulty in swallowing, speaking, and walking [4].  
Risk Factors for AD 
Age is one of the best known risk factors for AD. It is estimated to be ~5.4 million 
Americans living with AD, approximately 5.2 million are 65 years of age or older. [5]. 
There are two categories of age related onset of AD which are early and late onset. Early 
onset AD occurs before the age of 65 and accounts for 1-6% of AD cases [6]. Research 
have mapped mutations on chromosome 21 that encode the Amyloid Precursor Protein 
(APP) [7-9] as well as Presenilin 1 (located on chromosome 14) [10] and Presenilin 2 
(located on chromosome 1) [11]. There is evidence demonstrating that non-memory 
symptoms, such as language impairment, are more prevalent in early onset AD as well as 
a faster progression of cognitive decline and function [12]. The second category of age 
related AD is late onset, which is the most common, occurring at age 65 and older in about 
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90% of AD cases [13]. Mutations in APOE gene accounted for ~27% of late onset AD [14, 
15]. Advances in genome wide association studies have identified mutations in at least 20 
genes involved in late onset AD [16]. 
Heredity can be a risk factor of AD. Individuals who may have had a parent or sibling 
with AD are at a higher risk of developing this disease [17]; especially if genes 
containing mutations are inherited, such as in APOE. Environmental factors such as lack 
of physical activity, cardiovascular disease, and diet can contribute to AD. Lastly, 
individuals who have repeated occurrences of traumatic brain injury are at a higher risk 
of developing AD and other dementias [18].   
The Brain and AD 
In healthy individuals, the brain contains approximately 100 billion neurons, which form 
structures known as synapses whose function is to communicate with each other 
chemically by the release and uptake of neurotransmitters at the synapse. There are 
approximately 100 trillion synapses formed between the neurons in the brain. In AD, 
those neuronal functions are altered.  Brains of AD patients exhibit severe brain atrophy 
compared to brains of healthy individuals [19]. The reduction in the size of the brain is 
attributed to the loss of neurons and synapses which leads to the memory loss and decline 
of cognitive functions. At the molecular level, AD is characterized by the presence of 
amyloid beta (Aβ) plaques and neurofibrillary tangles. Aβ plaques are derived from 
proteolytic cleavage of amyloid precursor protein (APP) [20] (Figure 1.1). [21]). Aβ 
peptides begin as oligomers and can aggregate extracellularly in neurons leading to the 
deposition of Aβ plaques [22].The neurofibrillary tangles arise due to the hyper-
phosphorylation of the tau protein, which is a microtubule stabilizing protein, and 
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aggregates inside the neuron [23]. While the presence of Aβ plaques or neurofibrillary 
tangles are characteristic hallmarks of AD, there has been much debate on which one is 
the main culprit in AD pathogenesis [24, 25]. 
Amyloid Hypothesis 
The amyloid hypothesis states that deposition of Aβ is the initial contributor to AD 
pathogenesis and that Aβ leads to the formation of neurofibrillary tangles and neuronal 
loss [26]. There is a wide range of support for the amyloid hypothesis. Oligomeric Aβ42 
from AD brains is sufficient to induce synapse density, impair memory in rodents, and 
induce tau hyper-phosphorylation [27]. Furthermore, support for the amyloid hypothesis 
showing that mutations in in the genes that cause early onset AD increase Aβ levels [27]. 
Treatment for AD 
While there is no cure for AD, the amyloid hypothesis has driven exploration of AD drug 
therapies that focus on targeting Aβ, APP, or Presenillin1/2 [28] due to the fact that 
mutations in these genes lead to increase Aβ and early onset AD. One strategy for 
developing AD drugs is to target the proteases that cleave APP to generate Aβ. Those 
proteases are beta secretase and gamma secretase. β-secretase is the initial protease to 
cleave APP to generate Aβ [29, 30]. Drugs that inhibit β-secretase have been shown to 
reduce Aβ levels the in cerebral spinal fluid of AD patients [31]. The drawback from 
using inhibitors of β-secretase is that this protease has other protein substrates that have 
an important role in myelination and sodium homeostasis [32, 33]. Additionally, β-
secretase knockout mice have higher mortality rates as well as memory impairment [34].    
γ- secretase inhibitors have also been investigated as potential therapeutic targets. 
Cleavage by γ secretase is the final step in releasing Aβ from APP [35]. In principle, 
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inhibiting γ secretase would be a reasonable strategy to limit the production of Aβ. 
However, as with beta secretase inhibitors, γ secretase has additional substrates, such as 
Notch, which is essential for cell growth and differentiation [31, 36]. Recent clinical trials 
for γ-secretase inhibitors indicated severe negative side effects which were failure to slow 
the progression of AD and improve cognitive function [37, 38]. 
 A number of drugs have been designed to aid in Aβ clearance [39, 40]. This approach 
has been met with some challenges due to the fact that there is a need to identify 
biomarkers for AD in its early stages [41]. By the time AD symptoms are present, 
individuals could already be in the advanced stages of AD that may render this approach 
ineffective. Further research is needed to investigate drugs that target either beta or 
gamma secretase to modulate their levels specifically for APP, without causing 
deleterious effects on their other substrates. A complementary strategy that avoids off-
target effects that come from manipulating the secretases would be to directly modulate 
APP levels, since overexpression of APP contributes to AD pathology.  It will be 
informative to explore regulatory elements that enhance or suppress APP levels to shed 
light on mechanisms regulating APP.  
The Biology of APP 
 
The gene encoding APP is located on chromosome 21 and alternative splicing produces 
three major isoforms – APP695, APP751, and APP770 that  vary in their amino acid 
length [42].  APP751 and APP770 are expressed in most tissues whereas APP695 is 
predominantly in neurons [6, 42]. APP is a type I transmembrane protein that spans 
across the plasma membrane having the N-terminal region oriented towards the 
extracellular matrix while the C-terminal region is cytosolic [43]. APP contains a signal 
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peptide sequence and once it is synthesized in the endoplasmic reticulum and undergoes 
fast axonal transport to the plasma membrane [44] where it can be cleaved by proteases 
which release its extracellular, intracellular, and intramembrane domains [45]. 
Function of APP 
While APP has been extensively researched over the past few decades, the function of 
this protein is poorly understood. APP has been implicated in synapse formation, axonal 
migration, and synaptic plasticity [46]. Studies from APP knockout mice indicated that 
the mice had neurological deficiencies including grip strength and locomotor activity 
[47], as well as alter synaptic function and spine density as well as a reduction in spatial 
memory [48]. Additionally, upon examining overexpression of APP mice also showed 
defects in memory, altered synapse, and decrease in proteins responsible for synaptic 
plasticity [49]. 
It has been previously reported that APP could function as a cell surface receptor due to 
the similarities in processing with Notch [50, 51]. It was previously reported that Aβ 
could bind to APP suggesting that it could serve as a ligand for APP [52]. APP has also 
been shown to interact with extracellular matrix proteins such as heparin and laminin 
suggesting that APP could function as a cell adhesion molecule [53]. Additional evidence 
supporting a role for APP in cell adhesion comes from studies showing that APP can 
dimerize and that dimerization of APP stimulates the formation of specialized, 
presynaptic compartments in neuronal co-culture assays [54]. One of the most compelling 
arguments for the function of APP is in neurite outgrowth and axonal migration [55, 56] 
Proteolytic Processing of APP 
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APP cleavage is an orchestrated process that requires several sequential cleavage steps 
that occur in regulated intramembrane proteolysis (RIP). The RIP process enables the 
cells to respond to their extracellular environment by allowing the cleavage products to 
serve as signaling molecules that aid in a variety of biological processes. The first 
cleavage results the release of the protein’s ectodomain while the second cleavage occurs 
within the transmembrane domain releasing the protein’s intracellular domain [57, 58]. 
The RIP process of APP begins with cleavage by alpha secretase or beta secretase which 
occurs by two pathways that either precludes Aβ generation (termed Non-Amyloidogenic 
pathway) and one leads to the generation of Aβ (Amyloidogenic pathway) [58]. In the 
non amyloidogenic pathway, cleavage by alpha secretase occurs within the Aβ domain 
and releases the sAPPα ectodomain. Subsequent cleavage by gamma secretase releases a 
shortened Aβ peptide known as p3 and AICD. The amyloidogenic pathway begins with 
the cleavage of APP by beta secretase which releases sAPPβ ectodomain. APP is then 
cleaved by gamma secretase, where it releases AICD and Aβ (Figure 1.2 [59]) [58].   
Function of APP Cleavage Products 
The roles of the APP proteolytic products are poorly understood; however, investigations 
into their biological roles have been investigated. Initial cleavage of APP in the non-
amyloidogenic pathway by α-secretase releases sAPPα and a C-terminal fragment (CTF-
83). sAPPα appears to have more positive effects such as neuroprotective roles against 
oxygen/glucose deficiency through the inhibition of calcium currents and activating 
potassium currents [60, 61]. sAPPα also functions to promote neurite outgrowth and 
synaptogenesis [62]. There are no known biological functions for CTF-83. Cleavage by α 
and γ secretases release p3 which doesn’t have a clear biological function. In the 
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amyloidogenic pathway, initial cleavage of APP by β-secretase releases sAPPβ and CTF 
99. Neuroprotective functions are not attributed to sAPPβ. sAPPβ was demonstrated to be 
involved in axonal pruning by serving as a ligand for the death receptor 6 (DR6) and 
triggering apoptosis [63]. CTF 99 has not been shown to have a biological function. 
Cleavage of APP by β and γ secretases release the Aβ domain. Extensive research has 
been geared towards studying the toxic ramifications of Aβ accumulation, however, Aβ 
seems to have a relevant biological function. In small concentrations, Aβ was shown to 
depress neuronal activity [64], which is beneficial to prevent excitotoxicity. The last 
fragment, which is common to both non-amyloidogenic and amyloidogenic pathways, is 
the APP intracellular domain (AICD) that is released upon cleavage of CTF 83 or 99 by 
γ-secretase, producing a 57 or 59 amino acid sequence AICD. AICD acts as a signaling 
molecule that binds to Fe65 which then recruits the histone deacetylase Tip60 and 
together they translocate the nucleus to activate the transcription of several genes [65-67] 
Regulation of APP Gene Expression 
 
The levels of Aβ as well as the proteases responsible for its generation play a pivotal role 
in Alzheimer’s disease pathogenesis. While the regulation of the various genes involved 
in AD may be important, it may be just as important to understand how the expression of 
APP is regulated. Since APP is a substrate for beta and gamma secretase, the amount of 
Aβ generated from proteolysis of APP will depend on how much of the substrate is 
available for cleavage through the amyloidogenic pathway [68]. Increased expression of 
APP correlates with an increase in the production of Aβ. Evidence for APP 
overexpression in generating more Aβ comes from individuals with trisomy 21 who have 
higher amounts of APP mRNA when compared to control individuals [69, 70]. Mutations 
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in APP can also lead to increased protein levels and Aβ [71]. Additionally, certain 
regions of the brain contain more APP mRNA in AD patients than controls [72]. 
Therefore, it is important to understand the mechanism by which APP gene expression is 
regulated due to the fact that controlling the regulation of APP can also regulate the 
production of Aβ. To understand the mechanisms involved in regulating APP gene 
expression, we can examine transcriptional, post-transcriptional, and post-translational 
regulation of APP. 
Transcriptional Regulation of APP 
In order to investigate transcriptional control of APP, research has focused on the 
promoter region of APP. The promoter region of a gene contains cis-regulatory elements 
that enable the binding of proteins such as polymerases as well as transcription binding 
factors to promote or suppress transcription of a gene, thereby controlling the amount of 
protein being produced [73, 74]. Transcriptional analysis of APP revealed that the 
promotor region for the APP gene lacked a canonical TATA box region, but did contain a 
GC-rich region [74]. This GC-rich region is used to facilitate the binding of putative 
transcription factors [74]. Several transcription factors have been identified that bind to 
the APP promoter sequence. One transcription factor is the CCCTC binding factor 
(CTCF). This protein binds to a variety of DNA sequences and is also a regulator of c-
Myc which is involved in apoptosis [75]. CTCF has been shown to bind to a particular 
domain proximal to the APP domain designated as ABPβ. Binding of CTCF to 
ABP(beta) activates the transcription of APP [75]. Other transcription factors such as 
HSF1, which in response to stress, activates APP expression [76]; the NK-kB/Rel family 
has been shown to regulate APP in neuronal cells [77]. The transcription factor SP1 has 
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been shown to bind to the promoter of APP and the overlaps with CA1 transcription 
factor [78]. The promoter region of APP is conserved from rodents to primates with all 
having the absence of the TATA Box and all containing the GC-rich sequence, 
suggesting an important biological function between the promoter regions and the 
transcription factors that bind [74, 79]. This may be of importance considering that if 
mutations are found within the promote sequences, they could influence the binding of 
transcription factors that may increase transcription. A 2006 mutational analysis of the 
APP promoter region large study conducted on Belgian patients revealed six genetic 
variations within the promoter region of APP in which three of the variants lead to a 2-
fold increase in the transcription of APP [80]. In addition to the promoter region of APP 
influencing upregulation of the APP transcript, it has been previously shown that APP 
transcription can be influenced by local inflammation at sites of injury and was supported 
by research demonstrating that Interleukin 1, a pro-inflammatory cytokine, is secreted in 
response to brain injury and increases APP levels [81]. Further support of inflammation 
having an impact on APP mRNA levels comes from studies evaluating the effects of 
traumatic brain injury, a known risk factor for AD [82]. In one report, it was found that 
APP mRNA levels are upregulated in response to traumatic brain injury within 15 
minutes [83]. Additionally, genes and proteins involved in regulating APP mRNA levels 
are also increased following traumatic brain injury [84].   
Post-transcriptional Regulation of APP 
Once the APP mRNA is transcribed, it can post-transcriptionally regulated. This process 
is usually regulated by sequences found within the transcripts 5’ untranslated region 
(UTR), coding sequence, or 3’untranslated region. These sequences enable the binding of 
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RNA binding Proteins (RBPs) where they can either promote or suppress translation [85]. 
In the 5’ UTR, there are several regulatory elements that have been shown to regulate 
APP levels and influence its translation such as an internal ribosomal entry site (IRES), 
and iron response element (IRE), and an IL-1 enhancer response element [86-88]. 
Regulation of APP by the IRES was considered to regulate APP levels due to the fact that 
inhibition of the mTOR pathway, which is necessary for cap-dependent translation, still 
lead to an increase in APP levels [86]. This data lead to the finding of an IRES in 5’ 50 nt 
sequence in the APP 5’UTR which enable translation of APP via a cap-independent 
mechanism [86]. It was reported previously that APP contains an IRE stem loop that was 
similar the one, which in response to intracellular iron levels, regulates L and H ferritin 
mRNA [89]. IRP1 was found to bind to the IRE found in the 5’UTR of APP, where in the 
absence of iron, prevents cap-dependent translation of APP by blocking the 40S ribosome 
at the 5’ cap [89]. Interestingly, increasing iron concentrations influences APP mRNA 
translation by the IRES found in the APP 5’UTR. It remains unclear how the regulation 
of iron, or perhaps other factors, contribute to cap-dependent or cap-independent 
translation of APP mRNA. Lastly, the 5’UTR of APP contains a 90 nt region that 
interacts with IL-1, implicating a role for inflammation in regulating APP levels, which 
does not affect APP mRNA stability, but does regulate its translation [87]. 
The coding region of APP has been shown to be post-transcriptionally regulated by RNA 
binding proteins which influence its translation [90]. The Fragile-X Mental Retardation 
Protein (FMRP) has been predicted to bind to APP and act as a negative regulator of APP 
translation [91]. FMRP is highly expressed in the brain and mutations in the gene that 
encodes FMRP, FMR1, leads to reduction of the FMRP and causes Fragile X Syndrome. 
11 
 
Cognitive impairment is one of the major effects resulting from reduction of FMRP, 
which implicates this protein is necessary for normal cognitive function [92].  FMRP 
contains 2 major domains in which it interacts with its target mRNAs which are the KH 
domains, and second domain is a C-terminal RGG Box domain, which is a region rich in 
arginine and glycine repeats, is believed to interact with its mRNAs harboring guanine 
quadruplex structures [91-93]. High throughput sequencing methods such as HITs-Clip 
and PAR CLIP identified APP mRNA as a direct target for FMRP [94, 95]. Westmark 
and colleagues demonstrated that FMRP associates with APP mRNA through the coding 
region and negatively regulates its translation [96]. Additionally, knockdown of FMRP 
increased APP levels and Aβ levels. Additionally, stimulation with the mGluR agonist 
DGPH, rapidly increased APP mRNA translation [96, 97]. Another study demonstrated 
that FMRP associates with the coding region of the APP mRNA in Processing Bodies (P-
Bodies), which are cytoplasmic foci that are sites for mRNA suppression through mRNA 
nonsense mediated decay or microRNA induced silencing, where APP mRNA is 
translationally suppressed [98]. FMRP levels decline with age suggesting that FMRP 
transcripts would be elevated. This is concerning considering that age is a major risk 
factor for AD and that APP overexpression can lead to increased Aβ production.  Another 
RBP shown to bind to the APP mRNA coding sequence is Heterogeneous Nuclear 
Ribonuclear Protein C (HNRNP C). This protein belongs to a larger family of proteins 
that associate with pre-mRNAs in the nucleus and affect mRNA processing, metabolism, 
and transport [99]. This protein was shown to compete with FMRP for the binding site in 
the coding sequence where it promotes APP mRNA translation [98].  
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The 3’UTR of APP is ~1.2 kb in length and is conserved in all APP isoforms. Several 
regulatory elements have been identified in this region to regulate APP levels. 
Approximately 200 nucleotides downstream of the stop codon is a 29 nucleotide 
sequence that is suggested to de-stabilize APP mRNA and is the target sequence for 
Nucleolin [100]. Nucleolin is a major nucleolar protein and it is involved in chromatin 
decondensation, pre-rRNA transcription and ribosome assembly, and may have roles 
mRNA processing [101]. With the first 52 nucleotides of the APP 3’UTR is a region that 
stabilizes APP mRNA and is the binding site for six proteins, Rck/p54, plasminogen 
activator inhibitor-RNA binding protein 1 (PAI/RBP1), Y-box binding protein 1 (YB1), 
autoantigen La/Sjogren syndrome antigen B (La/SS-B) and elongation factor 1α (EF1a) 
[90]. It isn’t fully understood if these proteins operate together to regulate APP or what 
roles these proteins have individually in regulating APP with the exception of Rck/p54. 
Rck/p54 overexpression was shown to increase APP levels [102], presumably by using 
its helicase activity to unwind this region, making it more accessible to additional factors 
which stabilize APP mRNA. The next regulators of APP mRNA through its 3’UTR are 
microRNAs. miRNAs are small, endogenous RNAs that negatively regulate mRNA by 
binding to complementary sequences primarily in the 3’UTR of its target mRNAs [103, 
104]. There are two methods of negative regulation of gene expression by miRNAs 
depending on how they bind to their targets. One method is by binding with perfect 
complementarity to the sequence of the mRNA [105]. When this happens, the mRNA is 
degraded. The other method is by binding with near-perfect complementarity to the 
mRNA which enables the mRNA to be translationally suppressed [105]. Several miRNAs 
have been identified to bind to the 3’UTR and negatively regulate APP levels [106-108]. 
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Furthermore, it has been demonstrated that miRNAs are downregulated in AD [109-111]. 
Furthermore, single nucleotide polymorphisms (SNPs) have been identified in miRNA 
binding sites which alter miRNA regulation [112]. This suggest dysregulation of APP 
translation via miRNAs can contributed to higher APP levels, and can invariably lead to 
AD. More recently, a guanine rich region in the 3’UTR of APP was shown to adopt a 
secondary structure known as a guanine quadruplex (G-quadruplex) and was reported to 
negatively regulate APP levels [113].  Guanine rich nucleic acids can interact with one 
another through Hoogsteen-Hydrogen Bonding and are further stabilized by monovalent 
cations such as potassium [114, 115]. The data demonstrated that mutations in the G-
quadruplex region increased APP levels as well as Aβ levels [113]. The details of this 
regulation are mention in chapter 2. 
Post-translational Modification of APP 
Post-translational modification is the process of altering proteins once they have been 
translated. Some examples include APP is known to have several modifications such as 
N- and O- glycosylation, phosphorylation, and sialyation for example [45, 116, 117]. 
APP undergoes the constitutive secretory vesicle pathway in that once synthesized, it is 
transported to the endoplasmic reticulum (ER), then to the Golgi, and then to the plasma 
membrane before it’s internalized and trafficked to the endosome or lysosome [45]. APP 
exists as immature APP (iAPP) and during its transport from the ER and Golgi, APP is 
post-translationally modified by N and O- glycosylation and becomes mature APP 
(mAPP) [118]. N-glycosylation of iAPP takes place in the ER and O-glycosylation in the 
Golgi. After N and O-glycosylation, mAPP is secreted to the plasma membrane [118]. 
Proper glycosylation is needed in order to obtain proper axonal sorting and metabolism of 
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APP [119] (Figure 1.3 [117]). Studies have indicated that APP contains two sites for N-
glycosylation at Asn467 and Asn496  [120] and mutations of these sites prevents APP 
maturation and transport to the plasma membrane by retaining APP to the Golgi; leading 
APP to encounter Beta and gamma secretase to generate Aβ [121].  Additionally, APP 
bearing the Swedish and London mutations was shown to give rise to altered N-
glycosylation that contained high amounts of bisecting GlcNAc residues [122]. Several 
O-glycosylation sites have been identified in APP. These sites are in found on Ser and 
Thr residues and functions remains poorly understood [123]. O-glycosylation gives rise 
to mAPP and proteolytic cleavage of APP occurs preferentially after O-glycosylation 
[118]. It was reported that a mutation from the amino acid Leu to Pro was effective in 
inhibiting O-glycosylation of APP and in doing so, decreased the amount of mAPP [118]. 
Although this region is not usually a site for O-glycosylation [124], it is suspected this 
mutation could lead to improper folding of APP and could potentially prevent APP from 
being secreted and confined to the Golgi where the endocytic environment increases the 
change of APP cleavage by beta secretase [125-127]. Phosphorylation of APP has been 
shown to occur at Thr668 which allows for beta secretase cleavage of APP, but prevents 
gamma secretase, thus reducing Aβ [128]. 
Summary 
 
APP plays a pivotal in AD as proteolytic cleavage of this protein and overexpression are 
critical in the generation of Aβ. Given the lack of early indicators for AD and challenges 
facing the development of AD drugs, it is important to understand the mechanisms 
underlying regulation of APP gene expression and processing. Highlighted in this chapter 
are various regulatory elements that mediate APP expression and metabolism. Sequences 
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found within APP are capable of regulating its gene expression by promoting or 
suppressing transcription and translation of APP mRNA as well as serve as sites for post-
translational modifications. Mutations in APP can increase APP expression, alter 
cleavage and post-translational modification, and alter APP trafficking, all of which can 
increase Aβ levels. These data indicate the potential to uncover new pathways involved in 
mediating APP regulation and processing in efforts to develop new targets for AD 
treatment. 
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Figure Legends 
 
1.1 [21] (modified) Pathology of Alzheimer disease: (A) The two hallmark features of 
Alzheimer disease, β-amyloid plaques (arrowheads) and neurofibrillary tangles (arrows) 
in AD brain are revealed by the Bielschowsky silver stain. 
1.2  [59] (a) Two pathways (β/γ and α/γ) of APP proteolysis. APP can be cleaved by 
either β- or α-secretase, which is then followed by γ-secretase cleavage. The designation 
of substrates and products are depicted.  
1.3 [117] (modified): Schematic overview of the roles of glycosylation in the processing 
of APP. Correct glycosylation is required for axonal sorting and processing of APP. An 
alteration in N-glycosylation results in protein accumulation within the perinuclear region 
of the cell (1). Inhibition of the formation of N-glycans or complex N-glycosylation or 
sialylation of APP interferes with axonal sorting (2) and secretion (3) of APP, as well as 
the secretion of sAPPa (4), sAPPb (5), and Ab (6). 
 
 
 
 
 
 
 
 
 
17 
 
Figure 1.1 
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Figure 1.2 
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Figure 1.3 
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Abstract 
 
 A central event in Alzheimer’s disease is the accumulation of amyloid β (Aβ) 
peptides generated by the proteolytic cleavage of the amyloid precursor protein (APP). 
APP overexpression leads to increased Aβ generation and Alzheimer’s disease in humans 
and altered neuronal migration and increased long term depression in mice.  Conversely, 
reduction of APP expression results in a decreased Aβ levels in mice as well as impaired 
learning and memory and decreased numbers of dendritic spines.  Together these findings 
indicate that therapeutic interventions that aim to restore APP and Aβ levels must do so 
within an ideal range.  To better understand the effects of modulating APP levels, we 
explored the mechanisms regulating APP expression focusing on post-transcriptional 
regulation.  Such regulation can be mediated by RNA regulatory elements such as 
guanine quadruplexes (G-quadruplexes), non-canonical structured RNA motifs that affect 
RNA stability and translation. Via a bioinformatics approach, we identified a candidate 
G-quadruplex within the APP mRNA in its 3’UTR (untranslated region) at residues 
3008-3027 (NM_201414.2).  This sequence exhibited characteristics of a parallel G-
quadruplex structure as revealed by circular dichroism spectrophotometry.  Further, as 
with other G-quadruplexes, the formation of this structure was dependent on the presence 
of potassium ions.  This G-quadruplex has no apparent role in regulating transcription or 
mRNA stability as wild type and mutant constructs exhibited equivalent mRNA levels as 
determined by real time PCR.  Instead, we demonstrate that this G-quadruplex negatively 
regulates APP protein expression using dual luciferase reporter and Western blot 
analysis.  Taken together, our studies reveal post-transcriptional regulation by a 3’UTR 
G-quadruplex as a novel mechanism regulating APP expression. 
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Introduction 
 
 Amyloid plaques and neurofibrillary tangles are characteristic pathologic features 
of Alzheimer’s disease (AD), a progressive neurodegenerative disorder and the most 
common form of dementia [129]. Amyloid plaques are formed from the amyloid β 
peptide (Aβ), which is a proteolytic product of the amyloid precursor protein (APP). APP 
is a type 1 transmembrane protein that is ubiquitously expressed in humans [130]. While 
the biological function of APP remains obscure, a large body of work indicates that APP 
plays a critical role in AD pathogenesis via production of Aβ [130]. APP undergoes 
regulated intramembrane proteolysis (RIP) by one of two proteases, α- or β-secretase.  
Cleavage by α-secretase in the non-amyloidogenic pathway releases a secreted APP 
fragment (s-APP α) as well as a transmembrane α C-Terminal Fragment (CTF).  
Cleavage by β-secretase in the amyloidogenic pathway produces s-APP β and β CTF (for 
review see [45, 131-134]). APP CTFs can be further cleaved by β-secretase to produce p3 
and APP Intracellular domain (AICD) in the non-amyloidogenic pathway or Aβ and 
AICD in the amyloidogenic pathway [45, 134-136]. Aβ peptides can accumulate and 
form oligomers that eventually give rise to amyloid plaques [137]. The accumulation of 
Aβ oligomers can lead to synaptic loss and neurodegeneration [138]. Rare, early-onset 
forms of AD arise from mutations leading to elevated Aβ production.  This change in Aβ 
can arise from heightened APP levels due to mutations in APP or from increased APP 
copy number as observed in Down’s syndrome (Trisomy 21) [139, 140]. Early onset AD 
can also arise from elevated Aβ levels due to altered APP processing caused by mutations 
in the γ-secretase genes PSEN1 or PSEN2 [130].The accumulation of Aβ peptides is 
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thought to lead to tau hyperphosphorylation, which can result in synaptic dysfunction, 
neuronal death, and cognitive decline [64]. Elevated APP expression, and the associated 
increase in Aβ production via the amyloidogenic pathway, therefore has deleterious 
effects on both neuronal and cognitive function. 
Decreased levels of APP also lead to pathological changes in the brain, as 
revealed by studies investigating genetically modified mice that lack APP. Acute knock 
down of APP in neuronal precursor cells prevents these cells from migrating into the 
cortical plate [55]. Additionally, mice lacking APP exhibit defects in synapse formation 
that manifest as decreased dendritic spine abundance [141]. The synapses that do form 
exhibit altered plasticity, as they have impaired long term potentiation [48, 141, 142]. 
Therefore, as with overexpression of APP, reduced levels of APP lead to negative 
changes in neuronal structure and function. 
 
As both over- and under-expression of APP can be deleterious, identifying the 
endogenous mechanisms that normally maintain APP expression within the physiological 
range is of particular interest.  Regulatory sequences within the 5’ and 3’ UTRs 
(untranslated regions) of an mRNA can affect its stability, transcription, and translation 
and therefore contribute to the spatial and temporal regulation of gene expression [143-
147]. One mechanism whereby regulatory RNA sequences alter translation is through 
RNA secondary structures [148-150]. Guanine quadruplexes (G-quadruplexes), one such 
secondary structure [96, 115, 151], are DNA or RNA sequences containing repeating 
guanines arranged in a manner that facilitates intra-molecular assembly of stacks of 
guanine tetrads [114].  Stacking of these guanine tetrads is stabilized by monovalent 
cations, especially K+ and Na+ ions [151]. G-quadruplexes require two or more stacks of 
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guanine tetrads [152]. Both DNA and RNA G-quadruplexes form in cells [153, 154], 
although RNA G-quadruplexes are more stable than DNA G-quadruplexes [155].  
 
Here we investigated the endogenous mechanisms that regulate APP expression. 
The APP 3’UTR contains a variety of regulatory sequences that affect the stability and 
ultimately translation of the APP mRNA [90].  We show that a G-rich region in the 3’ 
UTR of APP is a G-quadruplex.  Further, we demonstrate for the first time that this 
sequence negatively regulates APP gene expression in a post-transcriptional manner.  
These findings are consistent with previous reports demonstrating that 3’UTR G-
quadruplexes can negatively regulate the expression of genes that harbor such structures. 
Moreover, our results suggest this secondary structure is a novel mechanism regulating 
APP gene expression and therefore may be an important factor contributing to AD 
pathogenesis.  
  
Materials and Methods:  
 
APP G-quadruplex identification and sequence conservation 
 
Using Quadparser, the sequence for APP mRNA (NM_201414.2) was searched for 
putative G-quadruplex sequences following the sequence motif (G≥ 2N1–7) 3G≥ 2 which 
defines four repeats of at least two guanines (G) interrupted by stretches of one to seven 
nucleotides of any type (N) [156]. Alignment for APP 3’UTR G-quadruplex sequence 
was performed using QGRS-H Predictor software [157] using GeneBank Accession 
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numbers as indicated in the text  for APP of different species. Potential G-quadruplexes 
were analyzed approximately 718 nucleotides downstream from the stop codon.    
 
RNA preparation 
 
RNA oligonucleotides (APP 3’UTR G-quad Wild type:                    
5’GGGGCGGGUGGGGAGGGG-3’) and (APP 3’UTR G-quad Mutant: 5’-
GGGGCGGGUGGGGAAAAA-3’) were purchased from Dharmacon, Inc. and 
Integrated DNA Technologies.  Li+ ions prevent Na+- or K+-induced G-quadruplex 
formation.  To ensure that G-quadruplexes did not form in the analyzed oligonucleotides 
prior to conducting experiments, the RNA was stored in buffers containing Li+ ions.  To 
replace cations in the RNA solution with Li+, RNA was dialyzed as described previously 
[158] in an eight-well microdialysis apparatus (Gibco-BRL Life Technologies) at a flow 
rate of 25 mL/min. The RNA was initially dialyzed with 100 mM LiCl for 6 h to replace 
the RNA backbone cation, followed by nuclease-free water for another 6 h to remove 
excess LiCl, and finally with 10 mM LiCacodylate (pH 7.0) overnight. Concentrations of 
the dialyzed RNA were quantified by UV-spectroscopy, and the RNA was stored at –
20oC until the experiments. 
 
Circular Dichroism (CD) Spectroscopy  
 
CD spectroscopy experiments were conducted based on a previously published protocol 
[158] using a Jasco CD J810 Spectropolarimeter and analyzed with KaleidaGraph v.4.5.2 
(Synergy Software). RNA oligonucleotides were prepared to a concentration of 2.5 µM 
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in 10 mM LiCacodylate (pH 7.0) by the dialysis procedure described above.  Prior to CD, 
RNAs were denatured at 95 C for 2 min and renatured at room temperature for 15 min 
for equilibration.  Spectra were acquired every nanometer from 220-310 nm at 25oC. 
Each reported spectrum is an average of 2 scans with a response time of 2 s/nm.  Data 
were normalized to concentration, oligonucleotide length and cuvette pathway to provide 
molar residue ellipticity values and smoothed over 5 nm [159].  
Data fitting 
 
CD-detected titrations were performed with KCl to determine the concentration of 
potassium ion (K+) required to drive G-quadruplex formation.  To determine K+1/2 values, 
ellipticity data as a function of K+ concentration were fit with KaleidaGraph v. 4.5.2 
(Synergy software) according to the apparent three-state Hill equation as previously 
described [158]. 
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where  is the normalized molar ellipticity, U is the normalized CD signal for fully 
unfolded RNA, I is the normalized CD signal for intermediate state RNA, and F is the 
normalized CD signal for fully folded RNA.  [K+1/2]1 and n1 are the K
+
1/2 and Hill 
coefficient values for the U-to-I transition, while [K+1/2]2 and n2 are the values for the I-
to-F transition.  Data were collected at the maximum wavelength (λmax) in the spectrum. 
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Constructs and Site-Directed-Mutagenesis 
 
The base vector for the luciferase experiments was pMIR-Report miRNA expression 
reporter vector which contains the firefly luciferase gene (Promega). To create the wild 
type (WT) construct, the entire 1.1 kb sequence of the APP 3’UTR (NM_201414.2) was 
placed 3’ of the Luciferase gene stop codon. To create a 3’UTR mutant construct, site-
directed mutagenesis (Stratagene, Quikchange mutagenesis kit) was carried out on the 
wild-type 3’UTR construct to mutate the final four guanine nucleotides of the G-
quadruplex to adenine nucleotides (5’-
CCCTGTTCATTGTAAGCACTTTTACGGGGCGGGTGGGGAAAAATGCTGGTCTT
CAATTAC-3’ and  5’-
GTAATTGAAGACCAGCATTTTTCCCCACCCGCCCCGTAAAAGTGCTTACAATG
AACAGGG-3’) [38]. Mutagenesis was confirmed by DNA sequencing (Macrogen).  
 
In order to create the human APP-APP 3’UTR over-expression plasmid, we amplified the 
coding region of human APP and sub cloned into the pmCherry-N1 vector using the NheI 
(5’-CGACGACGAGCTAGC ATGCTGCCCGGTTTGGCA-3’) and XmaI sites (5’-
TCGTCGTCGCCCGGGCGTTCTGCATCTGCTCAAAGAA-3’). The human wild-type 
3’UTR of APP was amplified and sub cloned 3’ of the APP stop codon using the AgeI 
site underlined (5’-CGACGAACCGGTACCCCCGCCACAGCAGC-3’) sense and (5’-
CGGCGGCGGACCGGTGCTCCTCCAAGAATGTATTTATTTAC-3’) antisense. The 
resulting plasmid was then subjected to site-directed mutagenesis (QuikChange; 
Stratagene) to change the final four guanine nucleotides of the G-quadruplex to adenine 
nucleotides [160] . Mutagenesis was confirmed by DNA sequencing. 
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Using these APP overexpression constructs bearing either the wild type or mutant 3’UTR 
G-quadruplex, we inserted a c-Myc epitope tag before the APP695 stop codon using site-
directed mutagenesis with mutagenic primers 
(5’gagcagatgcagaacgaacaaaaacttatttctgaagaagatctgtagcccgggatccac 3’ and 
5’gtggatcccgggctacagatcttcttcagaaataagtttttgttcgttctgcatctgctc 3’.)  The underlined 
nucleotide sequence corresponding to the c-Myc amino acid sequence “EQKLISEEDL.” 
Cell Culture and Transfection 
 
Experiments were carried out in HeLa and HEK293 cells (as indicated in the Results), 
purchased from the American Type Culture Collection (ATCC). Cells were cultured in 
Dulbecco’s modified Eagles medium (DMEM), supplemented with 10% fetal bovine 
serum, L-glutamine (2%), penicillin (25,000 U/ml) and streptomycin (25,000 g/ml). 
One day before transfection 4x105 naïve HeLa or HEK293 cells were seeded in 6 well 
plates. The next day, the medium was replaced with a transfection medium containing the 
plasmids and Turbofect (ThermoScientific) according the manufacturer’s instructions. 
For the metabolic labeling experiments, HeLa cells were transfected using Lipofectamine 
3000 (ThermoScientific) according to the manufacturer’s recommendations. Briefly, the 
HeLa cells were cultured in complete Dulbecco’s modified Eagles medium (DMEM) as 
described above. One day before transfection, HeLa cells were seeded in 10 cm tissue 
culture dishes such that they would reach 90% confluence the following day. On the next 
day, medium was aspirated and replaced with antibiotic free medium containing 10% 
FBS and 2%L-glutamine. APP-Myc constructs containing either wild type or mutant 
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3’UTR G-quadruplex sequence were transfected. 6 hours post transfection, transfection 
medium was aspirated and replaced with complete medium. 
 
Metabolic Labeling using L-azidohomoalaine (AHA) 
 
24 hours post transfection, cells in 10 cm dishes were prepared for metabolic labeling to 
examine newly synthesized proteins. Cells were washed twice with warm PBS. DMEM 
containing only high glucose was added to cells to deplete endogenous methionine and 
cysteine for 45 minutes. Next, the medium was replaced with DMEM containing 10% 
dialyzed FBS, 2% L-glutamine, .2 mM L-cysteine, 25 mM HEPES,  1 mM sodium 
pyruvate,  penicillin (25,000 U/ml) and streptomycin (25,000 g/ml), and 4 mM L-
azidohomoalanine (Click Chemistry Tools) for 4 hours. After this incubation period, cell 
lysates were collect in RIPA buffer and prepared for immunoprecipitation. 
Immunoprecipitation 
 
Following metabolic labeling of cells, lysates were prepared for immunoprecipitation 
using Dynabeads magnetic Protein G Beads (Life Technologies) following the 
manufacturer’s instructions. The antibody used for immunoprecipitation was 9B11 C-
Myc antibody (Cell Signal) to capture APP695Myc (wild type or mutant G-quadruplex) 
reporter constructs but not the endogenous APP. Following elution, 40% of the eluate 
along with the immunoprecipitation input and flow through were used for Western Blot 
Analysis to detect APP using the c1/6.1 mouse monoclonal antibody. The remainder of 
the eluate was used for the “Click Chemistry” reaction.   
 
30 
 
Click Chemistry Reaction 
 
To perform this reaction, IP eluate was subjected to the Click Chemistry Protein Reaction 
Kit (Click Chemistry Tools). In this reaction a desthiobiotin molecule containing an 
alkyne group forms a covalent bond to proteins containing the AHA labels (via the 
AHA’s azide group). This reaction followed the manufacturer’s instructions with the 
exception that the 30 min incubation time was changed to 1 hour. Following the reaction, 
samples were prepared for Western blot. 
Western Blot 
 
24 hours post transfection, cells were lysed in RIPA cell lysis buffer (50 mM Tris-HCl 
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40) containing 1X protease inhibitor 
cocktail (Thermo Scientific). Lysates were centrifuged at 14,000 rpm for 15 minutes at 
4°C. The resulting supernatants were transferred to a new microcentrifuge tube and the 
cell lysate protein concentration was determined using the BCA protein assay kit (Pierce) 
according to the manufacturer's instructions. 
Equal quantities of protein (~40 g) were mixed with loading buffer and loaded into the 
wells of 4–12% Bis-Tris polyacrylamide gels (Invitrogen) along with molecular weight 
standard (LiCor). Gels were run using MES running buffer and transferred to PVDF 
membrane (Immobilon PSQ, Millipore) using a semi-dry transfer apparatus (Owl 
Scientific) and NuPage transfer buffer (Invitrogen). After transfer, membranes were 
blocked with Odyssey Blocking Buffer (LiCor) for 1.5 hours. Next, the blocking buffer 
was removed and the membrane probed overnight at 4°C with blocking buffer containing 
C1/6.1 C-Terminal antibody (a gift from Paul Matthews;, 1:4000) and an antibody to β-
31 
 
actin (Sigma; 1:10,000) which were diluted in blocking buffer. Membranes were washed 
with 1X PBST for 5 minutes (4 times). After the washes, the membrane was probed for 1 
hour at room temperature with goat anti-mouse 2° Antibody (800 nm; LiCor) at 1:10,000 
diluted in blocking buffer. For the metabolic labeling studies, IRdye 800-conjugated 
Streptavidin (1:10,000; Licor) was used to detect proteins containing desthiobiotin. 
Membranes were washed extensively and then scanned using the LiCor Odyssey system. 
Band intensities were quantified using the Odyssey software.   
Luciferase Assays 
 
Cells were split the day prior to transfection and plated to 40-50% confluency in either 
24- or 96-well plates. On the day of transfection, media was aspirated and replaced with 
fresh media and plasmids transfected using Turbofect (ThermoScientific) according to 
the manufacturer’s instructions. An excess of pMIR-Luciferase plasmid was transfected 
relative to the transfection control plasmid (pRL-TK Renilla luciferase); a 40 to 1 molar 
ratio was utilized.  24 hours post-transfection, media was removed and Glo Lysis Buffer 
(Promega) was added to each well to lyse cells. These lysates were frozen (-80° C) prior 
to performing Dual Glo Luciferase Assay (Promega). Firefly Luciferase and pRL-TK 
Renilla luciferase activity were measured per the manufacturer’s instructions. In all cases, 
firefly luciferase values were normalized to Renilla luciferase values.  
RNA isolation and Real Time PCR 
 
To collect the lysates for RNA isolation, media from the 6-well plates was aspirated and 
replaced with 600 µL of RLP buffer (Qiagen, RNeasy Mini Kit) and 60 µL of β-
mercaptoethanol (Sigma). All equipment used in the RNA isolation procedure was 
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cleaned with RNaseZap (Ambion) solution. Total RNA was DNase treated by RQ1 
RNase-free DNase (Promega), and the RNA concentration was determined 
spectrometrically (Nano-Drop; Thermo Scientific). cDNA synthesis from total RNA 
utilized random primers (Invitrogen), Super Script II (Invitrogen), RNase H (Invitrogen), 
dNTPs (Invitrogen), and RQ1 (Promega).  Synthesized cDNA was utilized for real time 
PCR. We designed primers and probes for firefly and renilla luciferase (Firefly 
Luciferase primers- 5’-GCTATTCTGATTACACCCGAGG-3’, 5’-
TCCTCTGACACATAATTCGCC-3’,  5’-6-FAM-
TCCAGATCCACAACCTTCGCTTCAAA-TAMRA-3’; Renilla Luciferase primers-  5’-
CAAAGAGAAAGGTGAAGTTCGTC-3’,  5’-GTGGTAAACCTGACGTTGTAC-3’, 
5’-FAM-ATCATGGCCTCGTGAAATCCCGT-TAMRA-3’) and used these in 
combination with a BioRad 384 well real time thermocycler (CFX384). Taqman 
Universal PCR Master Mix was used following the manufacturer’s cycling conditions.  
Aβ ELISA 
 
Aβ40 ELISA (Wako) was performed using conditioned media from cells transfected with 
APP695 overexpression plasmids containing either the wild type or mutant G-quadruplex 
sequence following the manufacturer’s instructions.  
Statistical Analysis 
 
All experiments were repeated 3 times unless stated otherwise. All errors are shown as 
standard error of the mean. Equal variance was assumed for the two-sample student’s t-
test (95% confidence interval). Q test was used to reject outliers at the 95% confidence 
interval.  * indicates a P < 0.05, ** indicates a P < 0.01, and *** indicates a P < 0.001. 
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Results 
Bioinformatic identification and sequence conservation of an APP 3’UTR G-
quadruplex 
  
To investigate the post-transcriptional regulation of APP expression, we asked whether 
the human APP mRNA contains a G-quadruplex. Using Quadparser [156], we searched 
the APP mRNA sequence (NM_201414.2) for putative G-quadruplex sequences 
following the sequence motif, (G≥ 2N1–7) 3G≥ 2 which defines four repeats of at least two 
guanines (G) interrupted by stretches of one to seven nucleotides of any type (N). This 
approach predicted two putative G-quadruplexes within APP mRNA (Figure 1.1A). One 
such sequence is located within the protein coding region beginning at nucleotide 957, 
consistent with earlier findings [96]. This potential G-quadruplex is predicted to be 
relatively weak since it has the potential to form a quadruplex with only two stacks of 
guanine tetrads and the intervening loops are relatively long with 4 nucleotides each 
[161]. A second putative G-quadruplex was identified within the 3’UTR beginning at 
nucleotide 3008.  This 3’UTR sequence was recently identified independently by a 
bioinformatic analysis but was not experimentally investigated [162]. This putative G-
quadruplex could form a relatively strong G-quadruplex since it has the potential to form 
a quadruplex comprised of three guanine tetrads and the intervening loops are only 2 or 1 
nucleotides in length [152]. Since the G-quadruplex found in APP 3’UTR is 
approximately 718 nucleotides from the stop codon, we searched the APP gene of several 
species for potential G-quadruplexes around the same nucleotide distance from the stop 
codon and was able to obtain an alignment for the comparison of the genes using GQRS-
H Predictor software [157] (Figure 1.1B). The potential functional importance of this 
3’UTR G-quadruplex is highlighted by its conservation in APP genes in various species 
34 
 
(Figure 1B).  These findings suggest the presence of functional G-quadruplexes in the 
APP mRNA. 
Structural Confirmation of the APP 3’UTR Putative G-quadruplex 
 
To validate that the sequence identified by the bioinformatic approach is a bona fide G-
quadruplex, we performed a structural characterization of this sequence.  Several factors 
contribute to the folding of an RNA into a G-quadruplex, including the sequence itself 
(guanine tracts, loop sequence, and loop length) as well as the cellular environment (pH, 
temperature, and the concentration and identities of monovalent cations) [152, 163-165]. 
Importantly, potassium (K+) ions preferentially stabilizes G-quadruplex structures in 
comparison to sodium (Na+) and lithium (Li+) ions [166]. G-quadruplex formation can be 
monitored through key spectral signatures using circular dichroism (CD) spectroscopy. 
To test whether the 3’UTR sequence forms a G-quadruplex, we used an RNA 
oligonucleotide bearing the putative APP 3’UTR G-quadruplex and performed K+ ion 
titration monitored by CD. The first immediate observation is that CD spectra of this 
RNA includes a negative peak at 240 nm and a positive peak at 262 nm (Figure 2.2A), 
which are the distinctive CD signatures for a parallel G-quadruplex structure [158, 167]. 
We next investigated the K+ ion dependence of this G-quadruplex structure. Plotting the 
change in ellipticity versus K+ ion concentration revealed a three-state transition (Figure 
2.2B), with a K+1/2 of  ~3 μM and ~18 mM. As the physiological K+ concentration is 
~150 mM , this result suggests that the APP 3’UTR G-quadruplex is fully folded in vivo, 
with a maximum of 3-quartet planes. We then used CD to compare the oligonucleotide 
representing the wild-type APP 3’UTR G-quadruplex to the spectrum of the 
oligonucleotide representing a APP 3’UTR G-quadruplex sequence in which the fourth 
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set of G repeats was replaced with adenines (APP 3’UTR G-Quad Mutant) [160, 168].  
This was conducted in the presence of 150 mM KCl, which induces G-quadruplex 
formation in the wild-type sequence. In this mutated oligonucleotide we observed a 
significant decrease in the 262 nm peak, indicating a decrease in population of the G-
quadruplex fold (Figure 2.2C). Taken together, our CD data support the presence of a 
parallel G-quadruplex that is stabilized by K+ ions.  
The APP 3’UTR G-quadruplex does not regulate expression levels of the APP RNA 
 
We next investigated the functional significance of this G-quadruplex. As these structures 
can play roles in transcription, RNA stability and translation[151], we wanted to 
investigate what role the APP 3’UTR G-quadruplex has on gene expression. We began 
these studies by investigating whether the G-quadruplex regulated RNA levels, which 
would suggest a role in either transcription and/or RNA stability. To perform these 
studies, we utilized a luciferase reporter construct in which the human APP 3’UTR was 
inserted after the stop codon of the firefly luciferase gene [106].  To gain insight into the 
role of the G-quadruplex in regulating expression we created a parallel luciferase 
construct in which we disrupted the 3’UTR G-quadruplex structure by changing the 
fourth set of guanine repeats to adenines thereby disrupting tetrad formation [160, 168]; 
this mutant is analogous to the mutant oligonucleotide sequence used in the CD studies 
above. To test whether the G-quadruplex affected the expression levels of these 
transcripts, we transfected HEK293 cells with either construct using identical transfection 
conditions. Using qPCR to measure luciferase mRNA levels in these cell populations, we 
could detect no differences between luciferase mRNA having either the wild type or 
mutant G-quadruplex (Figure 2.3A). The APP 3’UTR G-quadruplex therefore does not 
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play any substantial role in regulating the expression at the level of transcription or RNA 
stability. 
The APP 3’UTR G-quadruplex Negatively Regulates APP Protein Levels 
 
We then investigated if the APP 3’UTR G-quadruplex plays a role in translation. The 
wild type and mutant luciferase reporter constructs were individually transfected into 
HEK293 cells. 24 hours post-transfection, we measured the luciferase activity as a proxy 
for luciferase protein expression levels from the two constructs.  Disruption of the G-
quadruplex structure significantly increased luciferase activity by 80% (Figure 2.3B) 
compared to the intact, wild type, G-quadruplex.  These findings were consistent with 
results obtained in parallel experiments using HeLa cells (data not shown) indicating that 
they are independent of the cell type. These findings suggest that translation is more 
efficient from the construct containing the mutant sequence than that containing the wild 
type G-quadruplex. 
We next sought to establish a system in which we could measure the effects of this G-
quadruplex on APP expression.  For these experiments, we used a plasmid encoding the 
695 amino acid isoform of human APP (APP695) followed by either the wild-type- or G-
quadruplex-mutated human APP 3’UTR. These constructs were transiently transfected 
separately into HeLa cells, which do not express the 695 amino acid isoform of APP 
[169, 170]. Cell lysates were collected 24 hours post-transfection and subjected to 
Western blot analysis. Consistent with previous findings [169, 170], we could not detect 
APP695 in untransfected cells (Figure 4A).  In contrast, transfected cells expressed readily 
detectable APP695 (Figure 2.4A). Therefore, we can specifically detect exogenous full-
length APP695 using Western blot analysis.  
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We then used this system to compare APP expression from cells expressing APP695 
followed by either the wild type or G-quadruplex-mutated 3’UTR.  Mutating the G-
quadruplex resulted in an approximate two-fold increase in steady state levels of full-
length APP695 (Figures 2.4A and 2.4B), consistent with the results obtained using the 
luciferase assay. To gain further insight into APP processing, we measured the abundance 
of the CTF that was produced from APP695 having either the wild type or mutant 3’UTR 
G-quadruplex. We measured the level of endogenous APP CTF in mock transfected cells. 
We then measured the levels of exogenous and endogenous APP CTF in cells transfected 
with the APP695 3’UTR WT G-quad and APP695 3’UTR Mutant G-quad constructs 
individually. We subtracted the intensity of the APP CTF band of mock transfected cells 
from that of cells expressing either of the APP constructs to obtain the effect of the 
3’UTRs on exogenous APP CTF levels (Figure 2.4C). This analysis revealed a 
significant increase in the amount of exogenous APP CTF in the mutant compared to the 
wild type control. We next investigated whether the increased APP expression led to 
increased production of Aβ peptides. As expected, ELISA quantification of endogenous 
and exogenous Aβ indicated that there was a 1.6-fold increase in A levels from cells 
transfected with APP containing the mutant G-quadruplex sequence compared to the wild 
type G-quadruplex (Figure 2.4D).  The effects we observe on APP proteolytic cleavage 
are due to increased APP expression that results from mutating the 3’UTR G-quadruplex. 
Taken together, these data indicate that the 3’UTR G-quadruplex negatively regulates 
APP levels. 
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Translational Control of APP by G-quadruplex 
 
Loss of the G-quadruplex leads to an increase in APP protein levels (Figure 2.4) without 
affecting the APP transcript levels (Figure 2.3A), suggesting a role for this structure in 
translational control. To test this prediction, we labeled newly synthesized proteins 
during a discrete window and asked whether more APP protein was produced from the 
construct in which the G-quadruplex was mutated. For these experiments, we used HeLa 
cells that expressed myc-tagged APP constructs followed by either the wild type or G-
quadruplex-mutated 3’ UTR (Figure 2.5A).  These cells were metabolically labeled for 
four hours with L-azidohomoalanine (AHA), a methionine analog that is incorporated 
into newly synthesized proteins during translation and can be subsequently detected using 
click chemistry-based approaches. In this approach a desthiobiotin molecule containing 
an alkyne group forms a covalent bond to the AHA molecule incorporated into newly 
synthesized proteins (Figure 2.5B) [171]. Specifically, we immunoprecipitated the 
exogenous APP using antibodies that recognize myc, biotinylated the AHA-containing 
APP, and used immunoblotting to determine the extent to which this immunoprecipitated 
APP had been synthesized during the labeling window (Figure 2.5C).  Using this 
approach, we determined that the mutant construct resulted in an increase in newly 
synthesized APP of 19.4% ± 5.3% (mean ± SEM; ratio paired t-test p = 0.0052; n=6) 
during the labeling window (Figure 2.5D).  Taken together with the previous findings, 
these results demonstrate that the 3’UTR G-quadruplex modulates APP protein 
expression by negatively regulating translation. 
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Discussion 
 
In this study, we have analyzed the human APP mRNA sequence for potential regulatory 
elements and identified a previously uncharacterized G-quadruplex within its 3’UTR. 
The formation of the intact RNA G-quadruplex was confirmed by CD spectroscopy. 
Importantly, this structure is stable at physiologic K+ concentrations.  Using two 
independent expression constructs, our results demonstrate that this G-quadruplex 
negatively regulates gene expression in a post-transcriptional manner. In addition to the 
negative regulation of APP via the 3’UTR G-quadruplex, we further showed that APP 
overexpression resulting from loss of regulation by the G-quadruplex led to increased Aβ 
levels. Further studies are needed to elucidate the mechanism by which the APP 3’UTR 
G-quadruplex regulates APP gene expression. 
G-quadruplex-forming sequences can be found throughout mRNAs, including within the 
5’UTR, coding regions, and 3’UTR. G-quadruplexes in the 5’UTR have the potential to 
suppress mRNA translation by blocking initiation factors binding [172] that are required 
for activating cap dependent translation initiation [173]. G-quadruplexes in the coding 
regions may have a role in stalling translational elongation [174, 175]. G-quadruplexes in 
the 3’UTR can be involved in translational repression [176], polyadenylation-dependent 
mRNA stability [177], and dendritic mRNA targeting [162]. Our data show that the G-
quadruplex found in the APP 3’UTR regulates APP gene expression at the translational 
level. 
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G-quadruplexes have been found in two other genes whose proteins play crucial roles in 
APP proteolysis and AD etiology – ADAM10 and BACE1.  The α-secretase ADAM10 
contains a 5’UTR G-quadruplex that represses translation [178]. BACE1, the β-secretase 
gene, contains an exonic G-quadruplex that drives BACE alternative splicing. Formation 
of this G-quadruplex produces a shorter, inactive BACE isoform, while disruption of this 
G-quadruplex results in the full-length, active BACE isoform which leads to increased 
Aβ production [179]. The presence of the G-quadruplex in these mRNAs may lead to 
coordinated regulation and cleavage of APP in response to specific cellular conditions. 
Previous work has demonstrated that G-quadruplexes may act as negative regulators of 
gene expression [180-184] and can exert their regulatory effects by interacting with RNA 
binding proteins that repress translation [185, 186]. Over three dozen proteins have been 
reported to bind the APP mRNA [90, 162, 187, 188]. Several of these proteins – 
including Nucleolin, hnRNP A, Fus, and  FMRP– bind to G-quadruplex sequences[186, 
189-193].  Whether these proteins interact with the G-quadruplex in the 3’UTR of APP is 
not known. Moreover, such proteins may interact with the G-quadruplex in concert with 
other factors; for instance, it has been shown for other mRNAs that RNA binding 
proteins that interact with G-quadruplexes can require additional protein co-factors to 
facilitate translational regulation [194, 195] . This remains an important area for future 
study. Additionally, recent studies have demonstrated that G-quadruplexes may interact 
with other translational regulators such as microRNAs [195, 196]. Overall, our results 
show that dysregulated APP translation due to disruption of the G-quadruplex in the 
3’UTR lead to elevated levels of APP. Since increased APP levels can lead to AD, it will 
be of interest to determine whether AD cases arise from dysregulated APP expression 
41 
 
due to mutations that disrupt the APP 3’UTR G-quadruplex and/or in the RNA binding 
proteins that interact with this sequence. 
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Figure Legends 
 
Figure 2.1. APP contains a putative G-quadruplex.  (A) Schematic of the APP mRNA 
that contains the putative G-quadruplex sequence in the coding region at position 957 (as 
identified by Westmark et al. 2007) and the G-quadruplex sequence in the 3’UTR 
(discussed in this paper) at position 3008. (B) G-quadruplex consensus sequence and 
comparison of the G-quadruplex sequence in the 3’UTR of human APP with the 3’UTR 
APP for other species.  
Figure 2.2. CD potassium ion titration of the APP 3’UTR G-quadruplex shows that 
it forms in vitro and is in parallel topology with 3-state folding. (A) CD spectra 
collected as a function of K+ ion concentration. K+-mediated G-quadruplex folding is 
performed at 2.5 µM RNA under 10 mM lithium cacodylate (LiCac) (pH 7.0), with K+ 
ion concentration ranged from 0 to 1 M. The positive peak at ~260 nm and negative peak 
at ~240 nm are CD signatures for parallel topology of G-quadruplex. (B) CD signal 
(ellipticity monitored at 262 nm) as a function of K+ ion concentration from panel A 
shows clear three-state transitions in G-quadruplex folding. The fitting was performed 
using equation 1 (see Material and Methods). At physiological K+ ion concentration 
(~150 mM), the G-quadruplex is fully folded. The K+1/2 and Hill coefficients (n) are 
provided in the plot. (C) CD titration and comparison of APP 3’UTR wild-type and 
mutant G-quadruplex sequence. 2.5 µM RNAs were used under 10 mM LiCac (pH 7.0) 
and physiological 150 mM or 0 mM K+ ion concentration The GGGG to AAAA 
substitution in the mutant disfavor G-quadruplex formation as evident by the reduction in 
CD characteristic signals for G-quadruplex (compare blue and red), and yield similar CD 
signal to the wild type sequence at 0 mM K+ ion concentration (green).  
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Figure 2.3. G-quadruplex regulation of Luciferase gene expression. (A) mRNA levels 
as assessed by qPCR and represented ΔΔCT values represents the normalization of the 
ΔCT  of firefly luciferase  to the ΔCT  renilla luciferase then normalized to the  wild type. 
(B) Quantification of Dual Luciferase Assay comparing the wild type G-quadruplex 
sequence to the mutant G-quadruplex sequence (G-quad Mut). Empty Firefly Luciferase 
plasmid was used as a control which does not contain the 3’UTR of APP. Firefly 
Luciferase values were normalized to Renilla Luciferase. 
 
Figure 2.4. G-quadruplex regulation of APP gene expression. (A) Western blot 
analysis of cells transfected with reporter constructs containing APP 695 coding sequence 
with wild type (G-quad WT) or mutant (G-quad Mut) sequence. Mock Transfection was 
used to confirm that these constructs were over-expressed in HeLa cells. Antibody C1/6.1 
recognizes both full-length APP695 and CTF. β-Actin was used as a loading control. (B-
C) Quantification of Western blots as in 4A with (B) APP levels normalized to β-Actin 
and (C) Endogenous CTF intensity values were subtracted from total CTF intensity 
values to obtain exogenous CTF values which were then normalized to β-Actin values. 
(D) Aβ ELISA quantification of total Aβ levels from conditioned medium of cells 
transfected with APP constructs containing the wild type or mutant 3’UTR G-quadruplex. 
Figure 2.5. G-quadruplex regulation of APP translation. (A) Western blot analysis of 
cells transfected with reporter constructs containing APP 695 coding sequence containing 
a C-terminal myc tag with either wild type (WT G-quad) or mutant (Mut G-quad) G-
quadruplex sequence. Mock transfection was used to confirm that these constructs were 
over-expressed. Antibody 9B11 (anti-Myc) was used to detect APP-Myc. (B) Schematic 
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representation of methods taken to identify newly synthesized APP (See methods). (C) 
Western blot analysis for immunoprecipitation demonstrating the successful pull down of 
Myc-tagged APP constructs (IP: using 9B11 anti myc mAb, IB: C1/6.1 anti APP). (D) 
Western blot analysis of total APP (top panel, IB: C1/6.1 anti APP) and newly 
synthesized APP (bottom panel, IB: Streptavidin). Statistical analysis was performed by 
normalizing the newly synthesized APP/Total APP (Streptavidin/C1/6.1) using a ratio 
paired t-test using Prism 6.0g for Mac. 
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Abstract 
 
Amyloid Precursor Protein (APP) plays a pivotal role in Alzheimer’s disease. Increased 
levels of APP correlate with an increase in amyloid β (Aβ), which is the cleavage product 
of APP. Cleavage of APP by β secretase and sequentially by γ secretase releases Aβ, 
which can then form aggregates leading to the accumulation of plaques seen in 
Alzheimer’s disease. While the functional role of APP is not well understood, research 
has shown that increased levels of the amyloid precursor protein lead to the increase in 
amyloid-β production.  Therefore, dysregulation of APP translation contributes to 
Alzheimer’s Disease. Translation is often regulated by cis regulatory elements in the 5’ 
and 3’ untranslated regions of the mRNA and by trans acting factors that recognize the 
sequences found therein. These regulatory elements primarily target the initiation step of 
translation, which is the rate limiting step in translation. Post-transcriptional regulation of 
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gene expression serves as a very important checkpoint between transcription and 
translation of the mRNA since the regulatory elements can influence mRNA stability, 
localization, and translation rate.  Therefore, it is important that normal levels of APP be 
maintained which is necessary for its function. Research from our lab and others has 
demonstrated that APP translation can be influenced by cis and trans regulatory elements. 
Here we focus on the APP 3’ untranslated region and how the regulatory elements found 
therein impact APP protein levels.  
Introduction 
 
The amyloid precursor protein (APP) plays a central role in the Alzheimer’s disease (AD) 
pathogenesis. APP is type 1 transmembrane that contains a large N-terminal domain 
which faces extracellularly as well as a smaller intracellular C-terminal tail [43]. APP can 
be alternatively spliced to give rise to eight different isoforms with 695, 751, and 770 
being the predominant isoforms. In the brain, APP is localized to presynaptic terminal 
axons as well as in dendrites [6, 42]. The biological function of APP is not well 
understood; however, APP can modulate neurite outgrowth and neuronal migration and 
has also been shown to play a role in synapse formation and maintenance [46]. APP can 
be proteolytically cleaved by secretases in one of two pathways referred to as the 
amyloidogenic pathway; which leads to the generation of amyloid beta(Aβ) and the non-
amyloidogenic pathway [58]. In the amyloidogenic pathway, APP is cleaved by β 
secretase releasing and subsequently cleaved by γ secretase to release the Aβ peptide. In 
the non-amyloidogenic pathway, APP is cleaved by α and γ secretases; however, α 
secretase cleavage occurs with the Aβ sequence and thus prevents Aβ from forming [58]. 
Therefore, APP and Aβ are plays a pivotal the pathogenesis of (AD).  
52 
 
In additional to proteolytic cleavage of APP to generate Aβ, over-expression of APP 
protein levels leads to an increase in the production of Aβ. APP is located on 
chromosome 21 and there has been research indicating that individuals with trisomy 21 
(Down Syndrome (DS)) are at a high risk of developing AD [9, 197, 198]. Several studies 
suggest there is a dose-dependent increase of APP in individuals with DS, as those 
individuals have an increase in APP levels which corresponds to an increase in Aβ levels 
[199]. Interestingly, individuals with DS develop an early onset of AD starting with 
evidence of neuropathological hall marks of AD, Aβ plaques and neurofibrillary tangles, 
around age 40 [9, 200]. In addition to over expression of APP due to trisomy 21, the 
Swedish mutation found in APP causes an increase in APP levels and increases the 
cleavage of APP by beta and gamma secretases, thereby releasing more Aβ [201, 202]. 
 Since APP protein levels can influence Aβ generation, it is important to understand how 
APP expression is regulated. APP expression can be regulated transcriptionally, post-
transcriptionally, and post-translationally [90]. Post-transcriptional regulation is an 
important intermediate between transcription and translation due the fact that several 
regulatory elements, such as RNA binding proteins or microRNAs, [203]. These 
regulatory elements are found throughout the APP mRNA; however, this review will 
focus on post-transcriptional regulation of APP from regulatory elements in the 3’ 
untranslated region (UTR) and it they regulate the translation APP.  
Overview of Translation 
 
Maintenance of cellular protein levels requires an orchestrated series of processes which 
includes mRNA processing, degradation, stability, localization, and translation [204]. 
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Previously, it thought that mRNA levels could be an indicator of protein abundance 
[205]; however, research has shown that mRNA levels poorly correlate with protein 
levels. Advances in technology has given insight into these regulatory processes that 
occur after an mRNA transcribed, and how they contribute to maintaining protein 
abundance [204]. Once an mRNA is transcribed, it is exported from the nucleus and 
serves as a substrate for translational control [206]. mRNAs are capped at the 5’ end and 
contains a poly-A tail at the 3’ end which promote the circularization of the mRNA and 
recruit translation initiator proteins, which in turn promotes translation [207, 208]. 
 Control of translation can be regulated by targeting global translation or by targeting the 
specific mRNA [206]. Translation consists of initiation, elongation, and termination. The 
primary target in translational control is the initiation step. In translation initiation, 
eukaryotic initiation factors (eIFs) eIF3, eIF4E, eIF4A, and eIF4G are involved in 5’ cap 
binding, recruiting the ribosomal subunit, bind to the Poly A Binding Protein at the 3’ 
end to circularize the mRNA [209]. Regulation of global translation occurs in part by the 
altering phosphorylation state of the eIFs [209]. One way to alter the eIFs’ 
phosphorylation state is by activating the mTOR pathway. The protein complex known 
eIF4 Binding Proteins (or eIF4BPs) compete for binding sites in eIF4E and eIF4G and 
inhibit translation initiation.  Activating the mTOR pathway phosphorylates the eIF4BPs, 
thus preventing their binding, and enable translation initiation to occur [208, 210].   
Besides global regulation of translation, complex regulatory networks exist to control the 
translation of specific mRNAs. Regulation of translation is not solely based on the naked 
mRNA for a substrate, but rather the interaction of RNA-RNA and protein-RNA 
complexes. This mechanism of translation depends largely on specific sequences found 
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within the mRNA; however, the untranslated regions (UTRs) at the 5’ or 3’ end primarily 
contains cis regulatory elements involved in post-transcriptional gene expression [211]. 
These sequences can facilitate the binding of RNA binding proteins (RBPs) or adopt 
secondary structures that promote or prevent the translation of a given mRNA [212]. 
While the 5’UTR contains sequences that play a role in post-transcriptional  regulation, it 
is clear that 3’ UTR contains a variety of regulatory elements that enables several modes 
of translational control at the 5’ and 3’ end [213]. 
Importance of the 3’UTR 
 
The 3’UTR has shown to play a role in translational regulation through the interaction 
with RNA binding proteins and microRNAs [214]. Moreover, several studies have 
researched the biological importance of the 3’UTR by investigating its length. 
Computational analysis revealed that mean 3’UTR length in human transcripts is about 
four times the length of its 5’UTR [215, 216]. Additionally, this study revealed that the 
3’UTR is longer than the 5’UTR from invertebrates to vertebrates [216].  Therefore, a 
given mRNA can contain multiple of regulatory sequences in the 3’UTR due to its 
length. Alternative polyadenylation (APA) sites found within the 3’UTR provides an 
example of how size of the 3’UTR matters in translational regulation. mRNA transcripts 
can have the same protein coding sequence, but differ in the 3’UTR sequences [214]. 
APA generally leads to the shortening of the 3’UTR and the consequence of that action is 
that other regulatory elements (such as RNA binding proteins or microRNAs) which 
depend on those sequences would be lost [217].    
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Regulation of APP by 3’UTR RNA Binding Proteins 
 
RNA binding proteins (RBPs) interact with mRNAs to regulate stability, function, and 
subcellular localization [203]. The mode of interaction between the RBPs and their target 
mRNA is through one or more RNA binding domains, that specifically bind to sequences 
found in the mRNA or by protein complexes that bind to the mRNA. APP expression is 
regulated by several RBPs via its 3’UTR. Approximately 200 nucleotides downstream of 
the stop codon is a 29 nucleotide sequence that is suggested to de-stabilize APP mRNA 
and is the target sequence for Nucleolin [100, 101]. Nucleolin is a major nucleolar protein 
and it is involved in chromatin decondensation, pre-rRNA transcription and ribosome 
assembly, and may have roles mRNA processing [218-220] and contains RNA and DNA 
binding domains [221]. Nucleolin physically binds to the 3’UTR of APP and causes a 
decreases in APP mRNA levels, APP protein levels, and reduces Aβ levels [222].  
The RNA heterogeneous nuclear ribonucleoprotein C (hnRNPC) binds to the same 29 
nucleotide base element [100] in the APP 3’UTR; however, it enhances APP mRNA 
stability and increases APP levels [100]. hnRNP C localizes predominantly to the 
nucleus, but it can shuttle into the cytosol [223] suggesting that this protein can regulate 
mRNA stability. This protein binds with specificity to UUUUU sequences [224], thus 
placing its binding to the 29 nucleotide sequence in the APP 3’UTR. The fact that both 
nucleolin and hnRNP C both bind to the same region suggest competition for this region 
to decrease APP mRNA and protein levels (as with nucleolin), or enhance its mRNA a 
protein levels (as with hnRNP C).  
Further examination of into the regulation of APP by both nucleolin and hnRNP C 
revealed that activation of the ERK pathway leads to an increase in the expression of both 
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proteins and that nucleolin first binds APP mRNA and destabilizes the mRNA. This is 
then followed by binding of hnRNP C where it enhances APP mRNA stability [225].  
A recent report demonstrated that HuD is involved regulating APP mRNA and stability 
and translation [226]. HuD Is predominantly found in neuronal cells where it is involved 
is learning and memory [227, 228]. HuD binds to the 3’UTR of APP where it enhances 
its stability and translation [226]. Furthermore, transgenic mice over-expressing HuD had 
increased APP and Aβ levels [226]. Additionally, upon examining brain tissues from 
patients with AD, it revealed significant increase in HuD, APP, and Aβ levels, 
demonstrating a role for HuD in AD [226].   
While protein-RNA interactions are involved in regulating APP translation, RBPs can 
interact can interact with other RBPs to regulate the translation of mRNAs by forming 
ribonucleoprotein particles [213]. Within the first 52 nucleotides of the APP 3’UTR is a 
region that stabilizes APP mRNA and is the binding site for six proteins, Rck/p54, 
plasminogen activator inhibitor-RNA binding protein 1 (PAI/RBP1), Y-box binding 
protein 1 (YB1), autoantigen La/Sjogren syndrome antigen B (La/SS-B) and elongation 
factor 1α (EF1a) (for review see [90]). It isn’t fully understood if these proteins operate 
together to regulate APP or what roles these proteins have individually in regulating APP 
with the exception of Rck/p54. Rck/p54 overexpression was shown to increase APP 
levels [102]. 
Indeed, APP mRNA stability and translation is regulated by RBPs. The RBPs recognize 
specific sequences with the APP 3’UTR or form protein complexes to regulate its 
translation. More research is needed to further characterize the interactions of the RBPs 
with APP mRNA. This can be achieved be examining the RNA binding domains within 
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these RBPs. Mutations within the APP 3’UTR or within the RNA binding domains of 
those RBPs could potentially alter APP protein levels and furthermore, downstream 
proteolytic cleavage to generate Aβ. 
Regulation of APP by microRNAs 
 
microRNAs (miRNAs) are important regulators of mRNA translation. miRNAs are 
small, endogenous RNAs that negatively regulate mRNA by binding to complementary 
sequences primarily in the 3’UTR of its target mRNAs [103, 104]. miRNAs are 
transcribed RNA polymerase II and is further processed into pri-miRNA by Drosha, and 
is exported to cytoplasm where it becomes mature miRNA by Dicer [229]. The mature 
miRNA is loaded on the RNA Induced Silencing Complex (RISC), which are comprised 
of the Argonaut (AGO) family of proteins that guide the miRNA onto its target mRNA 
sequence [230]. There are two methods of negative regulation of gene expression [100] 
by miRNAs depending on how they bind to their targets. One method is by binding with 
perfect complementarity to the sequence of the mRNA [105]. When this happens, the 
mRNA is degraded. Binding of miRNAs with near-perfect complementarity to the 
mRNA which enables the mRNA to be translationally suppressed [105]. Several miRNAs 
have been identified to bind to the APP 3’UTR and negatively regulate APP levels [106-
108]. Utilizing reporter constructs containing the intact and mutant miRNA target 
sequence within the APP 3’UTR, several miRNAs were reported to bind to the APP 
3’UTR and negatively regulate gene expression of APP reporter constructs as well as 
endogenous APP levels such as mir 106a, mir 106b, mir-17, mir 20a,[106, 231], mir-101 
[108], and mir-153 [232] among others.   
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 Furthermore, it has been demonstrated that miRNAs are downregulated in AD [109-
111]. Moreover, single nucleotide polymorphisms (SNPs) have been identified in miRNA 
binding sites which alter miRNA regulation [112, 233]. This suggests that dysregulation 
of APP translation via miRNAs can contributed to higher APP levels and can invariably 
lead to AD. 
Regulation of APP by Guanine Quadruplex 
 
Guanine rich RNA can adopt a secondary structure known as a guanine quadruplex (G-
quadruplex). Formation of the G-quadruplex occurs through Hoosteen hydrogen bonding 
between the guanine bases and are stabilized by monovalent cations such as potassium or 
sodium [151]. It is predicted to be as many as 376,000 G-quadruplex forming sequences 
in the human genome [156]. RNA G-quadruplexes are located in 5’UTRs, coding 
sequences, and 3’UTRs where they regulate mRNA localization [162] and predominantly 
suppress mRNA translation [115, 174-176, 234]. Recently, a G-quadruplex was identified 
in the 3’UTR of APP and the formation of this secondary structure was potassium 
dependent [113]. The intact G-quadruplex sequence negatively regulates APP protein 
steady state levels as well as APP translation [113]. Moreover, mutations in the APP 
3’UTR G-quadruplex sequence lead to higher expression of APP levels and an increase 
in Aβ levels [113]. Since over-expression of APP protein levels can lead to increased Aβ 
production, further understanding into the mechanism of how the G-quadruplex regulates 
APP is warranted.        
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Discussion 
 
Translational control of APP can occur by a variety of regulatory elements in the 3’UTR 
including sequences that facilitate the binding for RNA binding proteins, miRNAs, and 
more recently, adopt a secondary structure. RNA binding proteins can either enhance or 
suppress translation of APP; whereas miRNAs are involved in translational suppression. 
The G-quadruplex sequence acts as a negative regulator of APP translation. With so 
many regulatory elements in the same region, further research is needed to understand 
whether the above regulatory elements compete with one another for binding sites or if 
they cooperatively regulate APP levels. The RNA binding protein nucleolin was reported 
to bind G-quadruplex sequences as well as interact with the miRNA pathway, leading to 
mRNA decay [235]. It is currently unknown whether nucleolin binds to the G-quadruplex 
or interacts with the miRNA pathway in the APP 3’UTR.  
While this review focused on regulatory elements controlling the translation of APP in 
the 3’UTR, one cannot exclude regulatory elements in other regions of the APP mRNA. 
APP contains an iron response element that is involved in cap-dependent translation of 
APP [89] as well as an internal ribosome entry site (IRES) which promotes cap-
independent translation of APP [86] in the 5’UTR. Within the coding sequence of the 
APP mRNA is a predicted binding site for the RNA binding protein FMRP [96] which 
suppresses the translation of APP. hnRNP C was shown to compete with FMRP for the 
same site and thus increase APP translation when bound [98]; however, it is unknown 
whether hnRNP C competition with FMRP is dependent on the 29 nucleotide base 
element in to which it binds in the APP 3’UTR.  
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Regulation of APP by the 3’UTR G-quadruplex warrants further investigation. The role 
of G-quadruplexes in translational regulation of mRNAs is poorly understood. G-
quadruplexes are known to bind a variety of RNA binding proteins [193] to facilitate 
translational suppression of mRNAs that harbor such structures in their 3’UTR. 
Additionally, G-quadruplexes have been shown to contain binding sites for miRNAs 
[236] which demonstrates a possible synergistic interaction for controlling mRNA 
translation.  
In summary, dysregulation of APP protein synthesis mediated by the regulatory elements 
found within the APP 3’UTR could generate abnormal APP protein levels, which 
increases the chance of producing high amounts of Aβ. While translational control of 
APP is quite complex, elucidating the mechanism by which cis/trans regulatory elements 
control it translation will shed insight into therapeutic strategies for AD. 
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Abstract 
RNA sequences rich in guanine nucleic acids can adopt non-canonical secondary 
structures called a guanine quadruplex, which is achieved through Hoogsteen hydrogen 
bonding. RNA guanine quadruplex structures have been reported to regulate different 
aspects of mRNA metabolism such as mRNA splicing, localization, and translation. 
While several reports implicate guanine quadruplexes as important regulators of 
translation, the mechanism by which this secondary structure influence translation 
remains elusive. Previous work from our lab identified a guanine quadruplex structure in 
the 3’ untranslated region of the amyloid precursor protein. The amyloid precursor 
protein plays a critical role in Alzheimer’s disease pathogenesis in that it can be cleaved 
by proteases that releases its amyloid beta region. The accumulation of amyloid beta can 
lead to the formation of amyloid beta plaques, a central hallmark of Alzheimer’s disease. 
Additionally, over-expression of the amyloid precursor protein can lead to increased 
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production of amyloid beta. Therefore, further research into the mechanism by which the 
amyloid precursor protein is regulated. Our previous findings demonstrate that the 
amyloid precursor protein translation is negatively regulated by a guanine quadruplex in 
the 3’ untranslated region; however, how this regulation occurs remains unknown. We 
present here evidence demonstrating that the Fragile X Mental Retardation Protein and its 
paralog Fragile X Related Protein 2 binds to the guanine quadruplex sequence in the 3’ 
untranslated region of the amyloid precursor protein and regulate its expression. 
Introduction 
Deposition of amyloid-beta (Aβ) plaques and neurofibrillary tangles are molecular 
hallmarks of Alzheimer’s disease (AD) which is the most common form of dementia. Aβ 
is generated from proteolytic cleavage of its precursor molecule, the amyloid precursor 
protein (APP), by β- and γ- secretases in the “amyloidogenic pathway”. APP likely 
functions in synapse formation [237]; while increase in its Aβ fragment correlates with 
synaptic loss and dysfunction [64, 238, 239]. Additionally, increase in APP levels are 
implicated in the AD pathogenesis, as over-expression of APP leads to an increase in 
proteolytic cleavage by the amyloidogenic pathway [240, 241]. This claim is supported 
by research demonstrating that APP is located on chromosome 21, and individuals with 
Down Syndrome (trisomy 21) have increased APP levels [199, 242, 243]. Additionally, 
higher levels of APP are found in individuals that have the Swedish mutation [201]. In 
both instances, there is an increases in APP levels, as well as Aβ; moreover, these 
individuals develop clinical AD pathology much earlier (early-onset AD).   As APP is a 
substrate for β-secretase, over- production of APP provides more substrate to be cleaved 
in the amyloidogenic pathway. 
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 The data suggest that dysregulation of APP levels plays an important role in AD 
pathology. Our lab previously reported that APP contains a guanine quadruplex (G-
quadruplex) which negatively regulates its translation[113]. A G-quadruplex is a 
secondary structure formed in RNA (as well as DNA) rich in guanine nucleic acids. The 
guanine bases are able to interact with one another through Hoogsteen hydrogen binding, 
forming guanine tetrads, and are stabilized by monovalent cations such as potassium or 
sodium [115, 163]. G-quadruplex structures have been shown to have important 
biological roles such as mRNA spicing [244], localization [162], and mRNA translation 
[160, 168, 174, 178]. The primary role for G-quadruplex structures involves translational 
suppression; however, G-quadruplexes can promote translation via cap-independent 
mechanisms when located near internal ribosomal entry sites (IRES) [245].  
G-quadruplex structures serve as binding sites for RNA binding proteins (RBPs) which 
facilitate translational regulation. Several RBPs have been identified to bind to G-
quadruplex structures and repress translation such as nucleolin [195, 246] and FMRP 
[247-249]. While we previously reported that APP translation is negatively regulated by a 
3’UTR G-quadruplex in a post-transcriptional manner and that mutations in this sequence 
leads to increased APP and Aβ levels; however, the mechanism behind this regulation is 
unknown.  
 
APP is post-transcriptionally regulated by several trans binding factors such as RNA 
binding proteins [250]and miRNAs [106, 231]. It is currently unknown whether or not 
these proteins bind to the APP 3’UTR G-quadruplex. Utilizing mass spectrometry, we 
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were able to identify several proteins that bind to the G-quadruplex sequence located in 
its 3’UTR.  
We decided to investigate two proteins from our list, the Fragile X Mental Retardation 
Protein (FMRP) and Fragile X Related Protein 2 (FXR2P). FMRP is a ubiquitously 
expressed RBP that controls the translation of its target mRNAs generally by repression. 
A substantial trinucleotide CGG repeated in the 5’UTR of the fragile x mental 
retardation-1 gene leads to the repression of FMRP and causes Fragile X Syndrome, a 
common form of inherited mental retardation [251, 252]. FMRP contains three RNA 
binding domains, two KH domains and a domain rich in arginine and glycine called the 
RGG box [253]. The KH domains are believed to bind RNAs containing “kissing 
complex” motifs [254], while the RGG box has been shown to bind G-quadruplex 
sequences [248, 255]. APP mRNA in a target for FMRP and previous studies 
demonstrates APP translation is repressed by FMRP [96, 98]. However, it remains 
unclear whether FMRP binds to the G-quadruplex in the APP 3’UTR in order to 
regulation its translation.  
FXR2P is a conserved paralogue of FMR has the same RNA binding domains and binds 
to RNAs and polyribosomes suggesting a similar function in translational repression 
[256-259]. Little is known about the specific mRNA targets of FXR2P; however, it has 
been reported that FXR2P operates with FMRP to regulate circadian rhythm by 
regulating clock mRNAs [260] as well as regulate glucose metabolism in mice [261]. 
While FXR2P contains the RGG binding domain, it has only been shown for FMRP 
having the ability to use this region to bind G-quadruplex sequences [256].  Furthermore, 
APP mRNA has not been identified as a target of FXR2P. We present here evidence that 
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both FMRP and FXR2P bind to the APP 3’UTR G-quadruplex and regulates APP 
expression. 
 Materials and Methods 
 
Identification of putative APP 3’UTR G-quadruplex binding proteins 
 
Using the CLIPdb database, we searched the APP gene on chromosome 21 (position 
27252261 – 27544046 gene ID: ENSG00000142192 ) to determine whether proteins are 
predicted to bind to the APP 3’UTR G-quadruplex sequence. This sequence is located at 
positions 27253613 – 27253631 of chromosome 21. 
Database for Annotation, Visualization, and Integrated Discovery (DAVID): In order to 
categorize the proteins according to their biologically relevant functional roles, we used 
the DAVID database to group APP 3’UTR G-quadruplex binding proteins. Details about 
the specifics of this program can be found in  [262]. 
Cell Culture 
 
Experiments were carried out in HeLa and HEK293 cells (as indicated in the Results), 
purchased from the American Type Culture Collection (ATCC). Cells were cultured in 
Dulbecco’s modified Eagles medium (DMEM), supplemented with 10% fetal bovine 
serum, L-glutamine (2%), penicillin (25,000 U/ml) and streptomycin (25,000 g/ml). 
G-quadruplex pulldown experiments 
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RNA Oligonucleotide synthesis: RNA oligonucleotides corresponding to the wild type 
or mutant APP 3’UTR G-quadruplex sequence were synthesized by Integrated DNA 
Technologies (IDT) using the following sequences: 
Wild Type: 5’  GGGGCGGGUGGGGAGGGG-Biotin 3’ 
Mutant: 5’  GGGGCGGGUGGGGAAAAA-Biotin 3’ 
Folding of APP 3’UTR G-quadruplex oligonucleotides  
Folding of the APP 3’UTR wild type and mutant G-quadruplex oligonucleotides was 
performed as previously described [193]. 
Preparation of whole cell extracts  
Confluent HeLa cell cultures were washed with phosphate buffered saline (VWR) and 
lysed with polysome lysis buffer ((100 mM KCl, 5 mM MgCl2, 10 mM HEPES, pH 7.0, 
0.5% Nonidet P-40, 1 mM DTT, 100 U ml–1 RNasin RNase inhibitor (Promega), 2 mM 
vanadyl ribonucleoside complexes solution (Sigma-Aldrich) 25 μl ml–1 protease 
inhibitor cocktail for (Sigma-Aldrich)) on ice for 15 minutes then collected using a cell 
scraper.  
Binding of RNA oligonucleotides to streptavidin magnetic beads  
This procedure was performed using the method described in [193]. Streptavidin 
magnetic beads (LifeTechnologies) were initially incubated in blocking buffer containing 
10 mM Tris-HCl, pH 7.5, 100 mM KCl, Triton X-100, 0.1% (w/v) bovine serum albumin 
and 0.02% (w/v) tRNA from Saccharomyces cerevisiae (Thermo Fisher Scientific) for 1 
h at 4°C with rotation. Folded 3′-biotinylated RNA oligonucleotides incubated with the 
streptavidin magnetic beads at 4°C overnight with rotation. The following day, 500 μl of 
the protein extract was then incubated with streptavidin magnetic beads overnight at 4°C 
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with rotation. Bound proteins were eluted from the RNA by washing the beads with 
increasing KCl concentrations (150mM-2M). Each fraction was concentrated by 
trichloroacetic acid precipitation and analyzed on a 10% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), followed by silver staining 
(ThermoFisher) following the manufacturer’s recommendations, or western blot analysis 
using (for protein confirmation experiments) using primary antibodies for FXR2P (mouse 
1:5000 (Santa Cruz sc-56681) or FMRP (rabbit, 1:2000 (Sigma)) and secondary goat 
anti-mouse 2° Antibody (700 nm; LiCor) at 1:10,000 or goat anti-rabbit 2° Antibody (800 
nm; LiCor) at 1:10,000.  
Mass Spectrometry Analysis 
 
This procedure was performed by the Wistar Institute’s Proteomics Facility (University 
of Pennsylvania) Samples from the 1M and 1.5M elutions from the pull down 
experiments were subjected to 10% SDS-PAGE that was allowed to run 0.5 cm gel. The 
lanes cut out and digested with trypsin and analyzed the digests by LC-MS/MS on a Q 
Exactive Plus mass spectrometer using a 95min gradient. MS/MS spectra generated from 
the LC-MS/MS runs were searched using full tryptic specificity against the UniProt 
human database (www.uniprot.org) using the MaxQuant 1.5.2.8 program. Protein 
quantification was performed using unique+razor peptides. False discovery rates for 
protein and peptide identifications were set at 1%. 
Transfections 
One day before transfection HEK293 cells were seeded in 6 well plates so that they 
would be 80% confluent. The next day, transfection of the plasmids was carried out using 
XtremeGene HP (Sigma-Aldrich) following the manufacturer’s recommendation for 
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Turbofect (ThermoScientific) according the manufacturer’s recommendations for single 
transfection (Figure 4.4) or co-transfections (Figure 4.5). 
Western Blot Analysis 
 
24 hours post transfection, cells were lysed in RIPA cell lysis buffer (50 mM Tris-HCl 
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40) containing 1X protease inhibitor 
cocktail (Thermo Scientific). Lysates were centrifuged at 14,000 rpm for 15 minutes at 
4°C. The resulting supernatants were transferred to a new microcentrifuge tube and the 
cell lysate protein concentration was determined using the BCA protein assay kit (Pierce) 
according to the manufacturer's instructions. 
Equal quantities of protein (~40 g) were mixed with loading buffer and loaded into the 
wells of 4–12% Bis-Tris polyacrylamide gels (Invitrogen) along with molecular weight 
standard (LiCor). Gels were run using MES running buffer and transferred to PVDF 
membrane (Immobilon PSQ, Millipore) using a semi-dry transfer apparatus (Owl 
Scientific) and NuPage transfer buffer (Invitrogen). After transfer, membranes were 
blocked with Odyssey Blocking Buffer (LiCor) for 30 minutes. Next, the blocking buffer 
was removed and the membrane probed overnight at 4°C with blocking buffer containing 
A8717 (Sigma) which recognize APP (Figure 4.4) (rabbit, 1:1000) or Myc antibody 
9B11 (Figure 4.5) (Cell Signaling) (mouse, 1:5000) and an antibody to β-actin (Sigma; 
1:10,000). For Figure 5, a GFP antibody (Invitrogen) used to detect FMRP tagged with 
GFP (rabbit, 1:2000) and FXR2P (mouse 1:5000 (Santa Cruz sc-56681) antibody 
Membranes were washed with 1X PBST for 5 minutes (4 times). After the washes, the 
membrane was probed for 1 hour at room temperature with goat anti-mouse 2° Antibody 
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(700 nm; LiCor) at 1:10,000 diluted in blocking buffer or goat anti-rabbit 2° Antibody 
(800 nm; LiCor) at 1:10,000.  
Statistical Analysis 
 
All experiments were repeated 3 times unless stated otherwise. All errors are shown as 
standard error of the mean. Equal variance was assumed for the two-sample student’s t-
test (95% confidence interval). Q test was used to reject outliers at the 95% confidence 
interval.  * indicates a P < 0.05, ** indicates a P < 0.01, and *** indicates a P < 0.001. 
Results 
Identification of APP 3’UTR G-quadruplex Binding proteins 
 
G-quadruplex structures interact with RNA binding proteins that assist in translational 
regulation. In order to investigate potential proteins that bind to the APP 3’UTR G-
quadruplex, we performed a bioinformatic search of the APP 3’UTR for putative binding 
proteins. Using the CLIPdb data base, which attempts to ascertain the nucleotide binding 
sequences recognized by RNA binding protein-RNA interactions from publicly available 
CLIP-Seq data sets [263], in order to identify proteins that bind to the APP mRNA 
located on chromosome 21 (ENSG00000142192). Only 4 proteins were shown to 
recognize sequences in the APP 3’UTR that overlap with the G-quadruplex sequence 
(Table 1). Of the proteins that were predicted to bind to the APP 3’UTR containing the 
G-quadruplex, AGO 2 was an interesting find because it is a major component of 
microRNA Induced Silencing Complex (miRISC) pathway [230] and microRNAs have 
been shown to regulate APP levels [106, 231]. However, we wanted to confirm the 
results from the bioinformatic search using an alternative approach as G-quadruplex 
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structures may not crosslink very well with current HITS-CLIP or Par-CLIP methods 
[248].  
We next decided to perform a similar experiment used by von Hacht and colleagues to 
identify G-quadruplex binding proteins [193] by using the G-quadruplex sequence as bait 
to capture proteins. We synthesized RNA oligonucleotides (oligos) containing the intact 
APP 3’UTR G-quadruplex or the mutant G-quadruplex (previously described). Both 
oligos contained a 3’Biotin molecule which we used in our pulldown experiments 
(Figure 4.1A). We were able to bind our APP 3’UTR G-quadruplex oligos to 
streptavidin magnetic beads and used HeLa lysates to identify proteins that bound to 
wither the wild type or mutant G-quadruplex oligo. Following incubation of the HeLa 
lysates with either G-quadruplex oligo, proteins were eluted with increasing potassium 
concentration and the eluates were subjected to SDS-PAGE followed by silver staining. 
Figure 4.1B is a silver stain of proteins that bound to either the wild type (WT) or mutant 
(Mut) G-quadruplex sequence. We were specifically looking for differences in the bands 
from the silver stain in the WT or Mut elution lanes, or bands that were of a higher 
intensity in the WT elution lanes compared to the Mut elution lanes. The results indicate 
that are differences between elution lanes for both WT and Mut G-quadruplex lanes 
(indicated by the arrows in Figure 4.1B), suggesting that there are indeed differences in 
protein binding between the WT and Mut APP 3’UTR 3’G-quadruplex sequence.  
 
In order to identify which proteins were present in the WT and Mut elutions, we sent 
samples from WT and Mut 1 Molar (n=2) elutions for mass spectrometry analysis. Table 
2 is a list of the proteins identified from mass spectrometry. We focused on the proteins 
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the favored binding to the WT APP 3’UTR sequence, as the Mut sequence may not 
accurately represent proteins binding to that sequence due to the fact that we created the 
mutated sequence the Mut and it may not reflect a relevant biological interaction. We 
selected proteins that were identified in both mass spectrometry analysis and arranged 
them in order of their intensity fold change (Table 4.2 columns 1,2,3). To determine 
which proteins bound to the wild type APP 3’UTR G-quadruplex sequence, we examined 
the intensity fold change of each protein from each experiment. If the intensity fold 
change was greater than 1 for each experiment, we determined that protein to bind to the 
wild type sequence (Table 4.2 column 4). More than 1500 proteins identified by mass 
spectrometry, ~5% of the proteins identified favored binding to the wild type (WT) APP 
3’UTR G-quadruplex sequence.  Surprisingly, the only protein that was confirmed by 
mass spectrometry from the initial CLIPdp data base was NUDT21 (Table 1). The protein 
which had the highest values from two rounds of mass spectrometry analysis was the 
Fragile X Related Protein 2 (FXR2P). Interestingly, its paralog, the Fragile X Mental 
Retardation Protein (FMRP) was identified on our list and these two proteins were 
selected for further analysis.    
Confirmation of FMRP and FXR2P binding to APP 3’UTR G-quadruplex 
 
Our mass spectrometry analysis revealed the binding of FMRP and its paralog FXR2P to 
the APP 3’UTR G-quadruplex sequence. FMRP has been shown to bind G-quadruplex 
structures; however, FXR2P has not been shown, at least to our knowledge, to bind to G-
quadruplex sequences. In order to confirm the findings from our mass spectrometry 
analysis, we performed the same pulldown procedure using our biotinylated APP 3’UTR 
G-quadruplex oligos; however, after SDS-PAGE, we performed western blot analysis and 
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detected FMRP and FXR2P using antibodies that recognize those proteins. Figure 4.3 
indicates that both FMRP (Figure 4.2A) and FXR2P (Figure 4.2B) favors binding to the 
intact APP 3’UTR G-quadruplex sequence. This can be due to the fact that the intact APP 
3’UTR G-quadruplex sequence is folds into this secondary structure whereas the mutant 
sequences does not adopt this structure[113]. This data confirms our mass spectrometry 
analysis and suggests that the binding of FMRP and FXR2P to the APP 3’UTR G-
quadruplex may have a role in regulating APP expression.  
FXR2P Regulates APP Expression 
 
FMRP negatively regulates endogenous APP translation and has been previously reported 
[96, 98]; however, it is currently unknown whether FXR2P is involved in regulating APP 
levels. Given our previous results demonstrating FXR2P binds to APP 3’UTR G-
quadruplex, we wanted to investigate whether FXR2P can regulate APP levels. We over-
expressed FXR2P in HEK 293 cells to determine if there was any effect on endogenous 
APP levels. FXR2P over-expression was able to reduce APP levels when compared to 
mock transfected cells indicated by western blot analysis (Figure 4.3A). Upon 
quantification, over-expression of FXR2P lead to a .33-fold decrease in in endogenous 
APP levels which was statistically significant (p=0.001108) (Figure 4.3B). This is the 
first report demonstrating FXR2P regulates APP levels. This data suggests thatFXR2P 
has a role is regulating APP expression and warrants further investigation.   
 
Preliminary Data: FMRP and FXR2P regulates APP Expression via G-quadruplex 
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Regulation of APP by FMRP was demonstrated to occur by FMRP binding to a guanine 
rich sequence in the coding sequence of the APP mRNA [96]. Putative binding sites in 
the APP mRNA coding sequence were identified by HITC-CLIP experiments [94] and 
PAR-CLIP experiments [95]. While studies identify FMRP binding to the APP coding 
sequence, our data suggests that FMRP can bind to the APP 3’UTR G-quadruplex 
sequence. Additionally, the involvement FXR2P in regulating APP levels has not been 
investigated until now. Given the ability of both FMRP and FXR2P to bind to the G-
quadruplex sequence and that these proteins can regulate APP levels, we wanted to 
investigate whether regulation of APP expression by FMRP and FXR2P is mediated 
through the APP 3’UTR G-quadruplex. In order to address our question, we used a 
reporter construct containing the APP coding sequence fused to a c-Myc epitope tag as 
well as the APP 3’UTR sequence containing the intact or mutated G-quadruplex 
(previously described ), we co-transfected the APP reporter constructs with a GFP tagged 
FMRP plasmid or FXR2P plasmid in HEK 293 cells. Our preliminary results indicate that 
co-expression of our APP reporter construct harboring the intact G-quadruplex sequence 
with either FMRP or FXR2P reduces APP expression; however, that reduction is lost 
upon co-expression of FMRP or FXR2P with the APP reporter construct containing the 
mutant G-quadruplex sequence (Figure 4.4). Although this is preliminary data warrants 
additional experiments to determine the overall regulatory effect, it demonstrates for the 
first time that both FMRP and FXR2P may regulate APP expression through its G-
quadruplex sequence in the 3’UTR. 
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Discussion 
 
We previously identified the presence of a G-quadruplex sequence in the 3’UTR of APP 
and further demonstrated that it negatively regulates APP translation in a post-
transcriptional manner. In this report, we sought out to identify proteins that bind to this 
G-quadruplex sequence in order to further characterize how the G-quadruplex mediates 
translational regulation of APP. We report here our findings in which we identified 78 
putative RNA binding proteins from our mass spectrometry analysis that favor the 
binding to the intact APP 3’UTR G-quadruplex sequence. Of those 78 putative proteins, 
FMRP and FXR2P were selected for further investigation. Our results indicate, for the 
first time, that both FMRP and FXR2P bind to the APP 3’UTR G-quadruplex sequence. 
Furthermore, we report for the first time that FXR2P over-expression reduces APP 
expression. Lastly, we report preliminary data, which for the first time, indicates that 
FMRP and FXR2P reduce APP expression mediated by the 3’UTR G-quadruplex; 
however, additional experiments are needed to confirm this finding. 
FMRP and FXR2P contain conserved RNA binding domains such as the two KH 
domains and the RGG box. While FXR2P has not been shown to bind G-quadruplex 
sequence, FMRP has been shown to bind to such sequences through its RGG box domain 
[248, 264, 265]. Addressing whether FMRP, or FXR2P, uses its RGG box domain to 
bind to the APP 3’UTR G-quadruplex in order to regulate APP expression warrants 
further investigation. Additionally, it was reported that FMRP binds to the coding 
sequence of APP mRNA [96] and we cannot definitively rule out whether the guanine 
rich region in the coding sequence of APP alone is necessary for FMRP to regulation 
APP expression. Our preliminary data suggests that FMRP regulates APP expression 
75 
 
through the 3’UTR G-quadruplex, which may suggest that FMRP may selectively or 
preferentially use the G-quadruplex sequence to regulate APP expression, however, 
further experiments are needed to draw this conclusion. 
FMRP is a known regulator of translation and several modes of translational control by 
FMRP has been proposed. One model suggests that FMRP regulates mRNA translation 
by targeting translation initiation. This is achieved by FMRP recruiting CYFIP1 protein 
which then interacts with eIF4G protein, preventing its binding to the 5’ cap, thus 
inhibiting cap-dependent translation [266]. The next model for translational control by 
FMRP involves the miRNA pathway. FMRP was shown to interact with proteins 
involved in the miRNA pathway such as Argonaut 2 [267]. This would suggest that 
FMRP could regulate a subset of mRNAs through the miRNA pathway, which has been 
shown for PSD-95 [268]. Lastly, FMRP was shown to stall translation elongation by 
forming complexes that contained ribosomal proteins, mRNA, and additional proteins 
[94]. Later studies showed that FMRP binds directly to the ribosome, demonstrating that 
the KH domain could bind in between the large and small ribosomal subunits, thus 
stalling translation [269]. It is currently unclear how FMRP regulates APP translation and 
further experiments are needed to determine this mechanism   
 
Both FMRP and FXR2P seem to have the ability to reduce APP levels; however, it 
remains to be determined if they regulate APP levels cooperatively or independent of one 
another. One study reported that FMRP and FXR2P in a cooperative manner in order to 
regulate circadian rhythm [260]. Loss of FMRP and FXR2P in mice results in abnormal 
circadian rhythm due to dysregulation of CLOCK mRNAs in fmr1/fxr2 double KO mice 
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[260]. Circadian rhythm is dysregulated in AD [270, 271]. In addition, over-expression of 
APP levels leads to increased wake duration and decreased sleep as observed in 
transgenic mouse models over expression APP [272, 273]. As over-expression of APP 
leads to increased Aβ levels, studies have also demonstrated that increased Aβ deposition 
caused a decrease in sleep efficiency [274, 275]. Given our results indicating APP 
expression is regulated by FMRP and FXR2P, it might be of interest to further investigate 
this interaction and regulation in circadian rhythm. 
Our mass spectrometry results yielded several proteins that could interact with the intact 
APP 3’UTR G-quadruplex (Table 2). Further experiments are needed to determine if 
there are additional proteins that bind to this sequence and explore additional mechanisms 
of regulation. G-quadruplex sequences can target the initiation step in translation. One 
possible way this can be achieved is by proteins binding to the sequence and thus 
interfere with eukaryotic initiation factors in order to suppress translation or by 
sequestering these initiation factors to promote translation by cap-independent 
translation. Our results indicate that further exploration is needed to fully characterize 
how the APP 3’UTR G-quadruplex mediates translational control of APP expression and 
may provide additional insight into the regulation of APP and how it is involved in AD 
pathogenesis. 
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Figure and Table Legends 
 
Figure 4.1: Identification of APP 3’UTR G-quadruplex binding proteins: (A) 
Schematic of the procedure used to identify APP 3’UTR G-quadruplex binding proteins. 
APP 3’UTR wild type or mutant RNA G-quadruplex oligos were synthesized, each 
biotinylated at the 3’ end of the sequence. The G-quadruplex oligos were then used to 
capture proteins from HeLa lysates. The eluted proteins were then used for downstream 
applications such as silver staining and mass spectrometry analysis. (B) Silver stain of the 
SDS-PAGE gel from the eluted proteins. The proteins were eluted by increasing KCl 
[1M-1.5M] concentration. (WT)= wild type G-quadruplex sequence, (Mut)= mutant G-
quadruplex sequence. The beads lanes were used as a control since no RNA oligo was 
used to bind to the streptavidin magnetic beads; therefore, no proteins were eluted in 
these lanes. Arrows indicate differences in band intensities between the WT and Mut 
lanes.  
Figure 4.2: Confirmation of FMRP and FXR2P binds to the APP 3’UTR G-
quadruplex sequence: FMRP and FXR2P were selected from our mass spectrometry list 
to confirm whether these proteins bind to the APP 3’UTR G-quadruplex sequence. 
Following the same procedure used in Figure 4.1A, only this time western blot analysis 
was performed following KCl [500mM -1.5M] elution of proteins and probed for (A) 
FMRP or (B) FXR2P. Asterisk indicates the expected migration of the target protein. 
Figure 4.3: FXR2P over-expression reduces endogenous APP levels: FXR2P was 
over-expressed in HEK 293 cells. Following transfection, HeLa lysates were collected 
and used in SDS-PAGE followed by western blot analysis (A) Top gel is the probe for 
APP, middle lane is the probe for FXR2P, and the bottom gel is the probe for β-actin 
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which was used as a loading control. (B) Quantification of the western blot in (A). Y-axis 
represents the APP levels normalized to β-actin. X-axis represents the samples containing 
FXR2P (+FXR2P) over-expression or without FXR2P over-expression (-FXR2P) (n=4) 
p= 0.001108. 
Figure 4.4 Preliminary Data: FMRP and FXR2P regulates APP expression via APP 
3’UTR G-quadruplex: GFP-tagged FMRP and FXR2P were co-transfected with APP-
Myc_3’UTR reporter constructs harboring either the wild type or mutant G-quadruplex in 
HEK 293 cells. Following transfection, lysates were collected, subjected to SDS-PAGE 
followed by western blot analysis. Top gel is the probe for APP using a Myc antibody, 
followed by the probe for β-actin (used as a loading control), followed by FXR2P probed 
gel, and lastly, the gel probed for FMRP. Lanes 1 and 4 control lanes that were not co-
transfected with wither FMRP or FXR2P.  
 
Table 1: Bioinformatic approach to identify putative APP 3’UTR G-quadruplex 
sequence: Using the CLIPdb database, we searched the APP gene on chromosome 21 to 
determine whether proteins are predicted to bind to the APP 3’UTR G-quadruplex 
sequence. This sequence is located at positions 27253613 – 27253631 of chromosome 21. 
The gene symbols and their target sequence location are listed. 
 
Table 2: Putative APP 3’UTR G-quadruplex binding proteins Identified by mass 
spectrometry: Proteins listed in this table indicate potential binding proteins to the APP 
3’UTR G-quadruplex. Listed are the gene names that were identified as well as the 
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intensity fold change between each experiment. Genes are listed according to the values 
of the intensity fold change. 
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Figure 4.1 
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(B) 
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Figure 4.2 
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Figure 4.3 
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Figure 4.4 
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Tables 
 
Table 4.1 
APP 3'UTR G-Quadruplex  Location on Chromosome 21: 27253613 – 27253631 
Gene Symbol Binding Region on Chromosome 21 
AGO 2 21: 27253620-27253640 
LIN28A 21: 27253620-27253640 
Mov-10 21: 27253540 - 27253620 
NUDT21 21: 27425620-27425640 
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Table 4.2 
  
Proteins 
found in 
Experiments 
 1 and 2 
Intensity Fold 
Change 
WT/Mut  
Experiment 1 
Intensity Fold 
Change 
WT/Mut  
Experiment 2 
WT>MUT MUT>WT 
FXR2 235990000.0 1.4 FXR2  -- 
NXF1 123580000.0 5.5 NXF1  -- 
LSM14A 61421000.0 2.3 LSM14A  -- 
RRP1 23769000.0 0.0  --  -- 
PEG10 17150000.0 1.1 PEG10  -- 
HNRNPR 11156000.0 1.3 HNRNPR  -- 
UPF3B 2213700.0 2.0 UPF3B  -- 
FXR1 121.6 -1.9  --  -- 
ALYREF 79.2 1.9 ALYREF  -- 
EIF4G2 54.4 1.4 EIF4G2  -- 
PRPF31 46.6 3.8 PRPF31  -- 
SCAF11 40.8 5.6 SCAF11  -- 
SART1 40.5 1.9 SART1  -- 
CCAR2 40.5 1.5 CCAR2  -- 
DYNC1H1 32.1 -1.0  --  -- 
UBAP2L 24.8 1.8 UBAP2L  -- 
SND1 23.7 -1.6  --  -- 
MRPS23 16.2 -2641800.0  --  -- 
MEPCE 14.5 -22626000.0  --  -- 
ILF3 12.2 1.2 ILF3  -- 
SERBP1 11.7 1.5 SERBP1  -- 
AKAP8 11.2 2412600.0 AKAP8  -- 
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LARP1 11.1 1.3 LARP1  -- 
ZNFX1 10.8 10065000.0 ZNFX1  -- 
STRBP 10.4 16996000.0 STRBP  -- 
EIF4G1 10.3 3.6 EIF4G1  -- 
CCAR1 8.7 5.8 CCAR1  -- 
EEF1A1 8.4 2.6 EEF1A1  -- 
DDX18 8.3 -1.0  --  -- 
LARP4B 8.2 -2.0  --  -- 
NUDT21 8.1 23.9 NUDT21  -- 
SART3 8.0 11.3 SART3  -- 
SNRPD1 7.9 -1.1  --  -- 
DDX5 7.8 1.1 DDX5  -- 
FAM120A 7.6 1.4 FAM120A  -- 
TCERG1 7.5 -1.3  --  -- 
HNRNPA1 7.4 1.5 HNRNPA1  -- 
MTHFSD 7.4 2.0 MTHFSD  -- 
YTHDC2 7.3 1.7 YTHDC2  -- 
CIRBP 7.3 1.2 CIRBP  -- 
POLR2A 7.3 1.5 POLR2A  -- 
ILF2 7.3 1.0 ILF2  -- 
POLR2B 7.2 1.1 POLR2B  -- 
HNRNPA0 7.2 1.4 HNRNPA0  -- 
DHX9 7.1 1.4 DHX9  -- 
HNRNPL 7.0 1.6 HNRNPL  -- 
RBM14 6.9 1.3 RBM14  -- 
SAFB 6.8 -11445000.0  --  -- 
UTP14A 6.5 -814410.0  --  -- 
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LARP4 6.5 -6.5  --  -- 
PABPN1 6.0 1.6 PABPN1  -- 
ATXN2L 6.0 -2.0  --  -- 
G3BP2 5.9 1.6 G3BP2  -- 
NOP14 5.9 0.0  --  -- 
ZCCHC6 5.6 1.5 ZCCHC6  -- 
MOV10 5.6 -1.2  --  -- 
ZFR 5.5 1.6 ZFR  -- 
RALY 5.4 -5.2  --  -- 
HDLBP 5.3 -2.6  --  -- 
CNOT1 5.1 8.2 CNOT1  -- 
FMR1 4.9 1.2 FMR1  -- 
NOP2 4.9 -1.8  --  -- 
NSUN2 4.9 3.0 NSUN2  -- 
USP10 4.8 -2.6  --  -- 
SUGP2 4.7 0.0  --  -- 
EXOSC10 4.7 -1.6  --  -- 
SYNCRIP 4.7 1.2 SYNCRIP  -- 
ADAR 4.7 -2.2  --  -- 
SRPK2 4.6 -1.1  --  -- 
ZNF326 4.6 3.4 ZNF326  -- 
RBM39 4.6 -4.6  --  -- 
DDX3X 4.5 1.1 DDX3X  -- 
SF3B2 4.4 1.5 SF3B2  -- 
HNRNPU 4.3 -1.5  --  -- 
PRKDC 4.2 -1.1  --  -- 
RAN 4.2 1.6 RAN  -- 
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NOP9 4.2 -1.2  --  -- 
RRP8 4.2 1.2 RRP8  -- 
HNRNPC 4.1 -1.5  --  -- 
EEF2 4.0 -3.3  --  -- 
PTBP1 3.7 -1.7  --  -- 
SNRNP200 3.7 1.1 SNRNP200  -- 
IGF2BP3 3.6 -1.0  --  -- 
TRIM56 3.6 1.6 TRIM56  -- 
NUFIP2 3.6 -2.1  --  -- 
NOP56 3.6 -2.3  --  -- 
GTPBP4 3.6 -42.6  --  -- 
NCL 3.5 1.8 NCL  -- 
FUS 3.5 5.4 FUS  -- 
DDX17 3.5 -1.2  --  -- 
PRPF8 3.4 -1.3  --  -- 
XRN2 3.4 1.0 XRN2  -- 
RBMX 3.4 -2.5  --  -- 
WDR46 3.3 0.0  --  -- 
ZC3H4 3.3 10.0 ZC3H4  -- 
RPS20 3.3 -2.2  --  -- 
SF3B4 3.2 1.8 SF3B4  -- 
DDX6 3.2 -1.9  --  -- 
MATR3 3.2 1.5 MATR3  -- 
ZC3H15 3.2 -1.5  --  -- 
DNTTIP2 3.2 0.0  --  -- 
EIF2S2 3.1 -1.5  --  -- 
SF3B1 3.1 1.1 SF3B1  -- 
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AGO2 3.0 -1.2  --  -- 
AGO3 3.0 -4576000.0  --  -- 
RPL10A 3.0 -7.7  --  -- 
TFAM 2.9 4.1 TFAM  -- 
RPS10 2.8 -24.5  --  -- 
SUPT5H 2.8 4.9 SUPT5H  -- 
PUF60 2.8 -1.3  --  -- 
CAPRIN1 2.7 -1.2  --  -- 
PRDX1 2.7 -1.2  --  -- 
KRR1 2.6 0.0  --  -- 
EIF2S1 2.6 -1.5  --  -- 
ZNF598 2.5 -1.3  --  -- 
RPS7 2.5 -4.9  --  -- 
FBL 2.5 -14.3  --  -- 
PSIP1 2.5 1.5 PSIP1  -- 
EIF3A 2.4 4.7 EIF3A  -- 
ELAVL1 2.4 3.1 ELAVL1  -- 
DDX51 2.4 -1.0  --  -- 
ZC3HAV1 2.4 -1.5  --  -- 
PABPC1 2.4 -3.1  --  -- 
PES1 2.3 -2.3  --  -- 
PURB 2.2 2.0 PURB  -- 
RPS4X 2.1 -12.0  --  -- 
RPS3 2.1 -5.3  --  -- 
REXO4 2.0 -10.0  --  -- 
EIF4B 2.0 -1.0  --  -- 
EIF3C 2.0 1.6 EIF3C  -- 
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DHX57 2.0 -2.3  --  -- 
RBM19 2.0 -1.7  --  -- 
EIF3D 1.9 4.4 EIF3D  -- 
EIF3L 1.9 1.6 EIF3L  -- 
DDX24 1.9 -4.2  --  -- 
POLRMT 1.9 0.0  --  -- 
PURA 1.9 -1.9  --  -- 
DIMT1 1.9 -2.8  --  -- 
KIAA0020 1.9 -12.7  --  -- 
FTSJ3 1.8 0.0  --  -- 
RBM3 1.8 1.3 RBM3  -- 
NOP58 1.8 -2.7  --  -- 
DDX21 1.8 -6.7  --  -- 
LAS1L 1.8 -1051600.0  --  -- 
FAM98A 1.8 -3.4  --  -- 
CCDC86 1.8 -41.0  --  -- 
RPS3A 1.7 -4.7  --  -- 
PUS7 1.7 -1.9  --  -- 
NIFK 1.7 -19513000.0  --  -- 
UTP20 1.7 0.0  --  -- 
DDX1 1.7 -1.4  --  -- 
HNRNPM 1.7 1.0 HNRNPM  -- 
PABPC4 1.7 -2.7  --  -- 
RBM34 1.7 -19297000.0  --  -- 
PWP2 1.7 -4.0  --  -- 
RRP1B 1.7 -20.5  --  -- 
SRSF7 1.7 -1.3  --  -- 
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ABCF1 1.6 -1.2  --  -- 
CEBPZ 1.6 -41446000.0  --  -- 
STRAP 1.6 -2.4  --  -- 
LARP7 1.6 -1.6  --  -- 
NKRF 1.6 -2.3  --  -- 
U2AF2 1.5 1.4 U2AF2  -- 
RPL30 1.5 -32.5  --  -- 
UPF1 1.5 -2.2  --  -- 
NOC2L 1.5 -6551400.0  --  -- 
UTP3 1.5 -8002700.0  --  -- 
RPL22 1.5 -3.5  --  -- 
EIF4A3 1.5 3.9 EIF4A3  -- 
HNRNPAB 1.5 -1.3  --  -- 
GNL3 1.4 0.0  --  -- 
EIF3G 1.4 1.2 EIF3G  -- 
SRP14 1.4 1.3 SRP14  -- 
PUS1 1.4 -1.8  --  -- 
RTCB 1.4 -1.9  --  -- 
DDX50 1.3 -1772400.0  --  -- 
PARP1 1.3 -1.5  --  -- 
DDX27 1.3 -91147000.0  --  -- 
NOC3L 1.3 -4682100.0  --  -- 
RSL1D1 1.3 -104500000.0  --  -- 
RPL14 1.3 -350380000.0  --  -- 
NOLC1 1.3 1.2 NOLC1  -- 
SRSF9 1.2 -3545800.0  --  -- 
SRSF1 1.2 2.3 SRSF1  -- 
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CSDE1 1.2 -14.0  --  -- 
AQR 1.1 -3.3  --  -- 
NPM1 1.1 -2.4  --  -- 
NOP16 1.1 0.0  --  -- 
NSUN5 1.1 -2.2  --  -- 
RBM28 1.1 -26569000.0  --  -- 
TOP1 1.1 -7.2  --  -- 
NGDN 1.1 -12583000.0  --  -- 
ANKHD1 1.1 1.2 ANKHD1  -- 
BMS1 1.1 0.0  --  -- 
IMP3 1.1 0.0  --  -- 
PPAN 1.0 -17821000.0  --  -- 
MPHOSPH10 1.0 -4931900.0  --  -- 
RPL5 1.0 -3.5  --  -- 
DDX10 -1.0 -4373500.0  -- DDX10 
RPL15 -1.0 -14.1  -- RPL15 
HNRNPUL2 -1.0 -2944000.0  -- HNRNPUL2 
DDX31 -1.1 0.0  --  -- 
ABT1 -1.1 -2119500.0  -- ABT1 
NOL10 -1.1 -5248200.0  -- NOL10 
RPL4 -1.1 -15.6  -- RPL4 
DHX36 -1.1 -4.4  -- DHX36 
RPS26 -1.1 -19.2  -- RPS26 
NAT10 -1.2 -5.5  -- NAT10 
RPL35A -1.2 -10667000.0  -- RPL35A 
YTHDF2 -1.2 -1.8  -- YTHDF2 
RPS15A -1.2 -5.2  -- RPS15A 
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RPLP0 -1.3 -7.4  -- RPLP0 
RPS2 -1.3 -5.2  -- RPS2 
U2AF1 -1.3 4.2  --  -- 
TCOF1 -1.4 1.4  --  -- 
RPL27 -1.4 -20.9  -- RPL27 
RRP12 -1.4 0.0  --  -- 
GRWD1 -1.5 -1.4  -- GRWD1 
IGF2BP1 -1.5 -1.8  -- IGF2BP1 
RPL8 -1.6 -6.1  -- RPL8 
RPL21 -1.6 0.0  --  -- 
RPL7 -1.6 -24675000.0  -- RPL7 
RPL17 -1.7 -150480000.0  -- RPL17 
RPS24 -1.8 -7137600.0  -- RPS24 
RPL18A -1.8 -560530.0  -- RPL18A 
XRCC6 -1.8 -38.4  -- XRCC6 
SURF6 -1.9 0.0  --  -- 
RPL23A -1.9 -320340000.0  -- RPL23A 
RPL10 -1.9 0.0  --  -- 
RPL24 -2.0 0.0  --  -- 
SSB -2.1 -1.2  -- SSB 
YBX1 -2.4 -24.2  -- YBX1 
GNL2 -2.4 0.0  --  -- 
PAPD5 -2.5 0.0  --  -- 
RPL29 -2.5 -4.3  -- RPL29 
EIF5B -2.6 -1.6  -- EIF5B 
DHX15 -3.3 -8.2  -- DHX15 
GRSF1 -3.5 -1.4  -- GRSF1 
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RBM4 -3.6 -3.4  -- RBM4 
BRIX1 -4.0 31.5  --  -- 
RPS8 -4.4 -6946000.0  -- RPS8 
GTF2F1 -4.6 -1.2  -- GTF2F1 
EBNA1BP2 -5.6 0.0  --  -- 
HNRNPH1 -6.9 -3.8  -- HNRNPH1 
RPF2 -7.4 -2493000.0  -- RPF2 
DDX54 -8.6 0.0  --  -- 
RPL3 -17.6 -86988000.0  -- RPL3 
HNRNPH2 -92704000.0 -13749000.0  -- HNRNPH2 
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Chapter 5 
 
Summary of Research, Future Directions, Discussion 
 
Summary of Research  
 
We took a molecular approach aimed to find regulatory elements that control the 
expression of APP. APP is known to contain cis-regulatory elements within its mRNA 
sequence that regulates its protein levels. Furthermore, mutations in the APP gene leads 
to early onset AD. Our lab identified a guanine rich region in the 3’UTR of APP that 
folds into a guanine quadruplex structure, which negatively regulates its translation [113].  
Guanine rich RNA can adopt a secondary structure known as a guanine quadruplex (G-
quadruplex). Formation of the G-quadruplex occurs through Hoosteen hydrogen bonding 
between the guanine bases and are stabilized by monovalent cations such as potassium or 
sodium [151]. It is predicted to be as many as 376,000 G-quadruplex forming sequences 
in the human genome [156]. RNA G-quadruplexes are located in 5’UTRs, coding 
sequences, and 3’UTRs where they regulate mRNA localization [162] and predominantly 
suppress mRNA translation [115, 174-176, 234].  
The G-quadruplex was identified in the 3’UTR of APP is highly conserved, suggesting 
that it may have an important biological function (Figure 2.1). We used circular 
dichroism (CD) to investigate the structural formation (Figure 2.2) and further tested the 
formation of this secondary structure was potassium dependent (Figure 2.2). The G-
quadruplex was stabilized by K+ at physiological concentration, suggesting that this 
structure could fold within cells. Furthermore, mutating the G-quadruplex altered its 
stability, by preventing folding of this sequence (Figure 2.2). 
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  We next investigated whether the G-quadruplex sequence had any biological effect on 
APP levels [113]. We used a combination of reporter constructs containing the intact or 
the mutated G-quadruplex sequence (Figure 2.3 and Figure 2.4) Our results indicated 
that the intact APP 3’UTR G-quadruplex sequence negatively regulates reporter gene 
expression as well APP protein steady state levels and APP translation (Figure 2.4 and 
Figure 2.5). Moreover, mutations in the APP 3’UTR G-quadruplex sequence lead to 
higher expression of APP levels and an increase in Aβ levels (Figure 2.4). These results 
indicate, for the first time, that APP contains a 3’UTR G-quadruplex and that its 
expression is regulated by this sequence. Since over-expression of APP protein levels can 
lead to increased Aβ production, further understanding into the mechanism of how the G-
quadruplex regulates APP is warranted.        
We decided to continue looking into the mechanism by which APP expression is 
regulated by its 3’UTR G-quadruplex as a follow up from our published manuscript. 
There are numerous reports investigating post-transcriptional of gene expression by RNA 
G-quadruplexes. The major findings are that these structures serve a binding sites for 
RNA binding proteins that facilitate translation control of gene expression. We decided to 
investigate identify proteins that bind to this G-quadruplex sequence in order to further 
characterize how the G-quadruplex mediates translational regulation of APP. 
Summarized here are our unpublished findings and preliminary results findings in which 
we identified 78 putative RNA binding proteins from our mass spectrometry analysis that 
favor the binding to the intact APP 3’UTR G-quadruplex sequence (Table 4.2). Of those 
78 putative proteins, FMRP and FXR2P were selected for further investigation. Our 
results indicate, for the first time, that both FMRP and FXR2P bind to the APP 3’UTR G-
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quadruplex sequence (Figure 4.3). Our western blot analysis reveals that the binding of 
these proteins is stronger for the intact APP 3’UTR, and binds less favorably to the 
mutant sequence. This data suggests that the binding of FMRP and FXR2P is dependent 
of the folding of the APP 3’UTR G-quadruplex. Furthermore, we report for the first time 
that FXR2P over-expression reduces APP levels (Figure 4.4). Lastly, we report 
preliminary data, which for the first time, indicates that FMRP and FXR2P reduce APP 
expression mediated by the 3’UTR G-quadruplex; however, additional experiments are 
needed to confirm this finding. 
Future Directions 
 
Determine How FMRP and FXR2P Regulates APP Expression via G-quadruplex 
 
FMRP and FXR2P contain conserved RNA binding domains such as two KH domains 
and the RGG box. While FXR2P has not been shown to bind G-quadruplex sequence, 
FMRP has been shown to bind to such sequences through its RGG box domain [248, 264, 
265]. Addressing whether FMRP, or FXR2P, uses its RGG box domain to bind to the 
APP 3’UTR G-quadruplex in order to regulate APP expression warrants further 
investigation. Additionally, it was reported that FMRP binds to the coding sequence of 
APP mRNA [96] and we cannot definitively rule out whether the guanine rich region in 
the coding sequence of APP alone is necessary for FMRP to regulation APP expression. 
Our preliminary data suggests that FMRP regulates APP expression through the 3’UTR 
G-quadruplex, which may suggest that FMRP may selectively or preferentially use the G-
quadruplex sequence to regulate APP expression, however, further experiments are 
needed to draw this conclusion. 
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In fmr1 KO mice, high levels of APP and Aβ have been reported [96]. Both FMRP and 
FXR2P seem to have the ability to reduce APP levels; however, it remains to be 
determined if they regulate APP levels cooperatively or independent of one another. In 
fragile X syndrome, FXR2P cannot completely compensate for the lack of FMRP, which 
suggests that FMRP and FXR2P work together to regulate translation of mRNAs. While 
FMRP is known to suppress APP translation, FXR2P has not previously been shown to 
interact with APP or regulate its expression.  
Identify Additional Proteins that Bind APP 3’UTR G-quadruplex 
 
Our mass spectrometry results yielded several proteins that could interact with the intact 
APP 3’UTR G-quadruplex sequence (Table 4.2). It’s important to note that we only used 
the APP 3’UTR G-quadruplex sequence and the proteins identified may not reflect 
endogenous proteins that bind to the APP mRNA. Several proteins are known to bind G-
quadruplex structures [186] and it’s quite possible that the proteins which bind the APP 
3’UTR G-quadruplex, may not bind under endogenous conditions, but bind to the 
sequence only. One way to circumvent this caveat would be to use the protein which 
binds the G-quadruplex sequence and use that protein to pull down the APP mRNA from 
cell lysate. If identified protein is capable of pulling down the APP mRNA, we can then 
determine if the interaction is G-quadruplex dependent. Further experiments are needed 
to determine if there are additional proteins that bind to this sequence and explore 
additional mechanisms of regulation.  Several proteins from our mass spectrometry 
analysis bind to G-quadruplex in other mRNAs such as nucleolin [235, 276], which 
destabilizes APP mRNA and suppress its translation [101]; Fus [277], and G3BP2 [193] . 
G-quadruplex sequences can target the initiation step in translation. One possible way 
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this can be achieved is by proteins binding to the sequence and thus interfere with 
eukaryotic initiation factors in order to suppress translation or by sequestering these 
initiation factors to promote translation by cap-independent translation. Our results 
indicate that further exploration is needed to fully characterize how the APP 3’UTR G-
quadruplex mediates translational control of APP expression and may provide additional 
insight into the regulation of APP and how it is involved in AD pathogenesis. 
Identify Mutations or Single Nucleotide Polymorphisms in Endogenous APP mRNA 
Regulatory Elements 
 
mRNAs serve as the substrate for translation. Within the mRNA are cis regulatory 
elements which bind trans regulatory elements that facilitate translational control [212]. 
Therefore, mutations found within the cis regulatory elements could alter the binding of 
trans acting factors and mutations in trans acting factors could alter how they bind to the 
cis regulatory element and thus affect translation. We identified a new cis regulatory 
element known as the G-quadruplex in the 3’UTR of APP. The G-quadruplex negatively 
regulates APP translation [113]. We show preliminary data indicating FMRP and FXR2P 
binds to the G-quadruplex sequence and regulates APP translation. Future experiments 
will investigate whether mutations or single nucleotide polymorphisms (SNPs) exist in 
the APP 3’UTR G-quadruplex sequence. We hypothesize that mutations or SNPs could 
prevent G-quadruplex from properly forming and could increase APP levels. This was 
demonstrated by the mutations our lab produced in the APP 3’UTR G-quadruplex 
sequence and that those mutations prevented the folding of the G-quadruplex sequence 
and increased APP levels. Moreover, we identified proteins that bound to the intact G-
quadruplex sequence (unpublished data, Table 4.2). We would next investigate whether 
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mutations are found in those proteins, and further investigate whether those mutations 
alter their binding to the APP 3’UTR G-quadruplex and the consequence it has on 
regulating APP levels. 
Discussion 
 
G-quadruplex structure and function: From K+ stacking to K+ sensors? 
 
The work summarized in this thesis examined how the presence or absence of the G-
quadruplex regulated APP translation. Upon the observations in figure 2.2C, we noted a 
potassium mediated stacking of the APP 3’UTR G-quadruplex sequence. At intracellular 
potassium levels, this sequence would adopt a three-stacked G-quadruplex. However, we 
did not include the intermediate two-stacked G-quadruplex sequence, which would occur 
at a lower potassium concentration. Two-stacked G-quadruplex structures have been 
experimentally shown to be weaker and less stabilized structures when compared to G-
quadruplexes with more tetrad stacks [278]. However, two-stacked G-quadruplex 
structures are capable of regulating translation of mRNAs that harbor these structures 
[278, 279]. It’s not surprising that potassium mediates the stacking of the APP 3’UTR G-
quadruplex sequence.  It can lead one to speculate that changes in potassium 
concentration could cause a switch between a three-stacked to a two-stacked G-
quadruplex structure, and could possibly affect translational regulation for APP, since we 
previously showed that weakening the G-quadruplex sequence leads to increased APP 
levels. Potassium is the major intracellular ion whose concentration is higher inside of the 
cell [280]. The availability of potassium intracellularly could be a reason why this ion is 
preferred to stabilize G-quadruplex structures. It well known that potassium stabilizes G-
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quadruplex due to the fact that potassium has a larger atomic radius and can interact with 
two quartets within a G-quadruplex structure [281]. Potassium channels therefore could 
potentially influence G-quadruplex formation by modulating intracellular potassium 
levels.  Upon activation, potassium channels mediate the efflux of K+ ions [282]. Given 
that G-quadruplex stacking is dependent on potassium concentration, it would be 
interesting to determine if modulation of K+ could affect G-quadruplex stacking, and 
moreover, could have an effect on translation. Modulating potassium concentrations 
could provide a mechanism to induce localized translation of mRNAs through changes in 
intracellular K+ concentration by altering the stacking of the G-tetrads; therefore, G-
quadruplex structures could be used as a switch in response to K+ concentration and 
modulate translation. For instance, FMRP has recently been shown to have a function 
outside of regulating mRNA translation in that FMRP can regulate the activation of 
potassium channels. In particular, it was shown that FMRP interacts with the β4 subunit 
of BK channels [283], which are especially sensitive to calcium depolarization [284]. 
Binding to FMRP to the β4 subunit of BK channels promotes potassium efflux, which is 
able to increase membrane repolarization [283]. Could FMRP’s role in activating BK 
channels have an effect on the translation of FMRP target mRNAs that harbor G-
quadruplex structures stabilized by potassium concentration? Further exploration of this 
idea is warranted as this could provide a mechanism of localized translation.  
The challenge to investigate this idea is performing the appropriate experiment in cells. 
The vast majority of G-quadruplex studies have been investigated outside of cells. It has 
been experimentally validated that DNA G-quadruplexes could act as sensors to detect 
changes in potassium concentration [285]. A promising technique that was developed by 
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Liu and colleagues [286], utilized bimolecular fluorescence complementation which 
enabled them to study the formation of G-quadruplex structures under intracellular 
conditions in living cells. In their study, they used a RNA sequence which contained a G-
quadruplex sequence that was in close proximity to an aptamer tag. Additionally, a split 
eGFP protein was fused a protein bound which bound to the aptamer sequence as well as 
to the G-quadruplex sequence. Once inside the cell, the split eGFP tagged proteins were 
able to bind either to the aptamer or to the fully folded G-quadruplex sequence. Once the 
tagged proteins were able to bind to the sequences, it enabled the detection of the eGFP 
[286]. Mutations that prevented the formation of the G-quadruplex as well as lithium ion 
(which do not stabilize G-quadruplex structures) precluded the interaction of the split 
eGFP fusion proteins and therefore was not detected [286]. This technique could be of 
interest to study how G-quadruplex structures change in response to intracellular 
potassium concentrations and could provide insight into how those changes affect 
translation of mRNAs that harbor such structures.   
 
G-quadruplexes and miRNAs: Synergistic Regulators of translation?  
 
G-quadruplexes are located near miRNA binding sequences and proteins that bind to this 
structure can interact with the miRNA pathway [235, 287]. FMRP and Nucleolin have 
been shown to interact with AGO2 protein in the miRISC complex as well as G-
quadruplexes [189, 235, 287]. This data suggests that these proteins can participate in 
translational regulation with miRNAs. Several miRNAs repress APP translation through 
the 3’UTR [106, 231]. Of the miRNAs previously identified, one family of miRNAs, 
which includes has-mir-106a, 106b, and 17, are in close proximity to the newly identified 
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G-quadruplex sequence (Figure 5.1). These miRNAs are highly conserved and share a 
common miRNA binding sequence. We wanted to test whether miRNA regulations could 
be influenced by the presence or absence of the G-quadruplex sequence in APP. Using a 
luciferase reporter construct, we sub cloned the entire APP 3’UTR with either the wild 
type or mutant G-quadruplex sequence. Since miRNAs bind to their complementary 
sequences of its target mRNAs, we did not mutate the regions corresponding to their 
miRNA binding sites. If miRNAs regulate luciferase gene expression independent of the 
G-quadruplex, we would expect to see a decrease in luciferase expression in the presence 
or absence of the G-quadruplex. We used hsa-mir 106a and 153 for this experiments. hsa-
mir 153 is located ~ 220 nucleotides upstream of the has-mir 106a binding sequence. 
Both hsa-mir 106a and 153 negatively regulates APP expression through binding in the 
APP 3’UTR. Preliminary data in Figure 5.2 suggests that the APP 3’UTR G-quadruplex 
may influence miRNA mediated regulation of gene expression. However, additional 
experiments are needed.  
Since we did not mutate the miRNA binding sequences, the miRNAs should be able to 
bind and regulate gene expression; however, that is not case when we mutate the G-
quadruplex. One can speculate that other regulatory elements, RNA binding proteins 
perhaps, may be needed to bind the G-quadruplex structure in order to recruit miRNA 
machinery for translational repression. As the 3’UTR of APP contains several cis/trans 
regulatory elements, further exploration for how this factors influence APP translation is 
warranted. 
APP 3’UTR G-quadruplex Sequence is common to PPP2CB 
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We blasted the APP 3’UTR G-quadruplex sequence to determine how prevalent this 
sequence is in the human genome (Figure 5.3). The results indicate that the APP 3’UTR 
G-quadruplex sequence is very unique to the APP mRNA. One transcript, protein 
phosphatase 2 catalytic subunit beta (PPP2CB), was found to share the complete APP 
3’UTR G-quadruplex sequence in its 5’UTR. PPP2CB is the catalytic subunit of the 
protein phosphatase 2A. Protein phosphatase 2A plays a role in Alzheimer’s disease as 
downregulation of this proteins leads to tau hyperphosphorylation, which results in 
neurofibrillary tangles observed in AD brains [288]. As this sequence is known to form a 
G-quadruplex structure and regulate APP expression, there is opportunities to explore 
how this sequence regulates PPP2CB and how that affects the function of protein 
phosphatase 2A function. The  
APP, ADAM-10, and BACE contain G-quadruplex Sequence 
 
While the G-quadruplex sequence regulates APP expression, this secondary structure is 
also found in both β- and α- secretases. Both β- and α- secretases are the initial cleavage 
enzymes that lead to the amyloidogenic (β-secretase) or non-amyloidogenic (α-secretase) 
pathways [137]. The gene that encodes β-secretase is BACE1. BACE1 has a G-
quadruplex sequence in the located in exon 3 region which regulates its alternative 
splicing [289]. This G-quadruplex sequence leads to the proteolytically active full length 
BACE1, while mutations in this sequence give produces the inactive BACE1 transcript 
[289].  Additionally, ADAM-10, the gene that encodes α-secretase, has a G-quadruplex 
in its 5’UTR that that represses its translation [290]. Mutations in this G-quadruplex 
sequence results in increased cleavage of APP by α-secretase [290].  As APP, BACE1, 
and ADAM-10 expression can be regulated by G-quadruplex sequences, it will be 
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important to further investigate how this structure regulates the expression of these genes 
that play such pivotal role in AD.  
Concluding Remarks: 
 
Alzheimer’s disease (AD), the most common form of dementia, is a devastating 
neurological disease which results in synaptic dysfunction and neuronal loss. The 
accumulation senile plaques and neurofibrillary tangles are molecular hallmarks in AD 
pathogenesis, which arise from amyloid-β (Aβ) peptides and hyperphosphorylated tau 
protein respectively. Aβ deposition is at the core of the amyloid cascade hypothesis 
which postulates that elevated Aβ levels is the central event that leads to AD pathology 
[291]. Aβ peptides are produced by sequential, proteolytic cleavage of the amyloid 
precursor protein (APP) by β- and γ- secretases [137]. The biological function of APP is 
not well understood; however, APP can modulate neurite outgrowth and neuronal 
migration and has also been shown to be involved in synapse formation and maintenance 
[46].  
Indeed, proteolytic cleavage of APP leads to Aβ production and this effect is exacerbated 
due to over-expression of APP protein levels which leads to an increase in the production 
of Aβ. APP is located on chromosome 21 and research indicates that individuals with 
trisomy 21 (Down Syndrome (DS)) are at a high risk of developing AD [197, 198]. 
Several studies suggest there is a dose-dependent increase of APP in individuals with DS, 
as those individuals have an increase in APP levels which corresponds to an increase in 
Aβ levels [199]. Interestingly, individuals with DS develop an early onset of AD starting 
with evidence of neuropathological hall marks of AD, Aβ plaques and neurofibrillary 
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tangles, around age 40 [9, 200]. In addition to over expression of APP due to trisomy 21, 
the Swedish mutation found in APP causes an increase in APP levels and increases the 
cleavage of APP by beta and gamma secretases, thereby releasing more Aβ [201, 202]. 
While there is no cure for AD, the main strategies for therapeutic development are aimed 
at decreasing Aβ levels by targeting the enzymes that mediate its generation and to 
increase Aβ clearance [29, 30, 292].  Another strategy to find drug targets for AD, based 
on the amyloid hypothesis, involves identifying proteins or molecules that regulate APP 
protein levels. Given that over expression of APP contributes to AD pathology, it will be 
necessary to explore regulatory elements that could modulate APP levels. 
With the identification of the G-quadruplex sequence in the 3’UTR of APP and further 
demonstrating this sequence negatively regulates APP expression, there are additional 
opportunities for research aimed at investigating the mechanism of regulation by this 
sequence. By exploring proteins and additional regulatory elements that interact with the 
G-quadruplex sequence, it may provide further insight in our understanding of 
Alzheimer’s disease. 
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Figure Legends 
 
Figure 5.1: G-quadruplex is located near miRNA binding sites Schematic of APP 3’UTR 
sequence for miRNA binding and G-quadruplex. The red nucleotides correspond to the 
binding of miRNA family members 106a, 106b, and 17 in position 2980-3005 of the APP 
3’UTR. G-quadruplex sequence starts just 3 nucleotides from the ending of the miRNA 
binding sequence (position 3008-3027). 
 
Figure 5.2: Preliminary Data: G-quadruplex alters miRNA function: Quantification of 
dual luciferase assay from cells over-expressing miRNAs 106a and 153 with luciferase 
reporter constructs containing wild type (WT) or mutant (Mut) G-quadruplex sequence. 
Over-expression of miRNAs with the luciferase reporter (WT G-quadruplex) construct 
shows a decrease in luciferase levels. Conversely, over-expression of miRNAs with the 
mutant G-quadruplex luciferase construct failed to reduce luciferase levels. Y-axis is the 
amount of firefly luciferase gene expression normalized to renilla luciferase levels. 
 
Figure 5.3: Nucleotide Blast of APP 3’UTR G-quadruplex Sequence 
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Figure 5.1 
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